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Abstract 
Multiple sclerosis (MS) is a neuroinflammatory disease characterized by 
demyelinated neurons in the central nervous system. Decreased levels of the 
anti-inflammatory microRNA-146a have previously been observed in 
macrophages/microglia in MS patients compared to controls. Therapeutically 
elevating microRNA-146a expression in MS may produce a conducive 
environment for remyelination. Inflammatory cytokines were assessed from both 
primary mouse and human macrophages and microglia, and THP-1 
macrophages that were transfected with a microRNA-146a mimic and polarized 
towards a pro-inflammatory phenotype. Inflammatory cytokines and MS-relevant 
targets were measured following activation; neuro- and oligodendrogenesis were 
also assessed in vitro while the effect of microRNA-146a on myelin phagocytosis 
was also examined. MicroRNA-146a may decrease pro-inflammatory TNF but 
may have little to no effect on IL-6; RhoA may decrease in both mouse and 
human macrophages. MicroRNA-146a increased myelin phagocytosis of 
unstimulated primary mouse microglia. Finally, in vitro experiments suggest that 
supernatants collected from LPS-stimulated murine macrophages transfected 
with a microRNA-146a mimic do not affect neurogenesis or oligodendrogenesis. 
It is suggested that increasing microRNA-146a may promote an anti-inflammatory 
environment beneficial for promoting remyelination in MS. 
Keywords: multiple sclerosis; microRNA-146a; macrophage; microglia; 
remyelination; neurogenesis; oligodendrogenesis.
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Chapter 1 - Introduction 
1.1 Overview of Multiple Sclerosis 
Multiple sclerosis (MS) is a neuroinflammatory disease characterized by 
demyelinated neurons in the brain and/or spinal cord. This disease affects twice 
as many females as males (Multiple Sclerosis International Federation 2013b), 
and the average age of onset of MS worldwide is 30 years (Multiple Sclerosis 
International Federation 2013b). According to the latest Atlas of MS 2013 report 
database by the MS International Federation, Canada has the highest MS 
prevalence in the world, with 291 people developing MS per 100,000 people 
(Multiple Sclerosis International Federation 2013a).  
Central to MS pathology is the destruction of myelin sheaths that normally 
ensheath the axons of neurons. Myelination increases the rate, the energy 
efficiency, and the refractory period of electrical signals along a neuronal axon 
(Blank and Prinz 2014). If myelin sheaths are damaged, electrical signals along 
these demyelinated neurons are diminished (Smith et al. 1979), which can 
clinically manifest into patients developing highly heterogeneous neurological and 
physical symptoms. These symptoms can include syndromes associated with the 
brainstem, muscle weakness and/or paralysis, spasticity, fatigue, sensory and 
cognitive impairment, depression, sensitivity to heat, headache, myelitis, and 
optic neuritis (Gelfand 2014). 
MS is clinically diagnosed using the revised 2010 McDonald Criteria 
(Polman et al. 2011). These criteria utilize two clinical biomarkers to support an 
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MS diagnosis: examining magnetic resonance imaging (MRI) scans that are T2-
weighted with or without gadolinium-enhancement, and measuring 
immunoglobulin G (IgG) synthesis in the cerebrospinal fluid (CSF) by calculating 
the IgG index and/or observing oligoclonal bands (Polman et al. 2011). MRI 
scans are used to identify lesions, while gadolinium is used to provide evidence 
of blood-brain barrier (BBB) breakdown (Housley et al. 2015). Relapse onset and 
severity can be predicted based on the size and number of lesions found on MRI 
scans (Housley et al. 2015). The IgG index (the ratio of IgG/albumin in CSF to 
IgG/albumin in serum (Perkin et al. 1983)) or presence of oligoclonal bands 
indicates potentially pathological intrathecal IgG synthesis (Bonnan 2015; Fortini 
et al. 2003). Apart from MRIs and examining CSF IgGs, other potential MS 
biomarkers being examined for their diagnostic validity include myelin-reactive T 
cells, genetic biomarkers, messenger ribonucleic acids (mRNAs), and micro 
ribonucleic acids (microRNAs or miRNAs) (Housley et al. 2015).  
MS may manifest itself in a variety of forms upon initial investigation, and 
can progress in distinct patterns. Clinicians have classified three general MS 
disease courses (or phenotypes) that can develop: relapsing-remitting MS 
(RRMS), secondary progressive MS (SPMS), and primary progressive MS 
(PPMS) (Lublin and Reingold 1996; Lublin et al. 2014). First, RRMS may begin 
as a clinically isolated syndrome (CIS), which is defined as the initial clinical 
presentation of a characteristic inflammatory demyelinating disease but requires 
meeting dissemination in time criteria to suggest an MS diagnosis (Lublin et al. 
2014; Miller et al. 2005). If the CIS becomes active and meets MS diagnostic 
 3 
criteria, the CIS transitions into RRMS (Lublin et al. 2014). RRMS consists of 
pronounced acute attacks with full or partial recovery and no apparent disease 
progression between attacks (Lublin and Reingold 1996; Lublin et al. 2014). 
Approximately 85% of patients are first diagnosed with RRMS (Multiple Sclerosis 
International Federation 2013b). Second, SPMS patients have a disease course 
initially defined as RRMS, but it transitions into disease progression with or 
without plateaus, minor relapses, and/or minor remissions (Lublin and Reingold 
1996). It is suggested that approximately 58% to 80% of patients with RRMS 
transition into SPMS (2012; Scalfari et al. 2014; Tremlett et al. 2008). Third, 
PPMS patients have disease progression from the onset of symptoms, with or 
without plateaus and/or minor improvements in disability (Lublin and Reingold 
1996). It is estimated that approximately 10% (Koch et al. 2009) of patients with 
MS have PPMS. To measure the extent of clinical disability in all forms of MS, the 
Kurtzke Expanded Disability Status Scale (EDSS) (Kurtzke 1983) is used. This 
scale ranges from 0.0 to 10.0, where neurological and physical disability 
increases as the score increases, ending at death with a score of 10.0 (Kurtzke 
1983). 
Epidemiological and genome-wide association studies have identified 
several factors that increase the risk of developing MS. There is evidence that the 
human leukocyte antigen (HLA) HLA-DRB1*15:01 allele is positively associated 
with MS susceptibility in European populations (Hollenbach and Oksenberg 
2015). Viral infection by Epstein-Barr virus (EBV) is also associated with an 
increased MS risk (Levin et al. 2010). Furthermore, there is evidence to suggest 
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that CD4+ T cells may cross-react between myelin and EBV antigens (Lunemann 
et al. 2008; Wucherpfennig and Strominger 1995). Non-infectious environmental 
risk factors can include smoking (Hedström et al. 2009) and low levels of vitamin 
D (Munger et al. 2006). Smokers have an increased risk of developing MS, but 
nicotine was ruled out as a possible risk factor (Hedström et al. 2009). High levels 
of vitamin D in blood serum is also associated with a reduced risk of MS (Munger 
et al. 2006). Besides factors influencing MS in general, factors influencing MS 
phenotype have also been identified. In one study, more females than males tend 
to be in the SPMS population (Tremlett et al. 2009), and exposure to EBV may 
possibly increase risk of developing RRMS over PPMS (McKay et al. 2015). 
Besides relapsing disease, there are also factors that can influence progressive 
disease. For example, the male gender and the onset of motor symptoms was 
associated with a faster time from disease onset to SPMS (Koch et al. 2010). In 
contrast, regarding disease progression in PPMS, the onset of sensory 
symptoms was associated with a delayed clinical progression to an EDSS score 
of 6.0 (Koch et al. 2009).  
1.2 Immunopathology and Recovery in Multiple Sclerosis 
 
MS is considered to be an immune-mediated disease, where T and B cells 
of the body coordinate the destruction of the body’s own myelin sheath by 
directing phagocytic cells, including microglia and blood-derived macrophages. 
White matter (Kutzelnigg et al. 2005) and grey matter (Damasceno et al. 2014; 
Kidd et al. 1999; Peterson et al. 2001) can be damaged. How the demyelinating 
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attack may begin is still unclear. One general idea is the “inside-out, outside-in 
hypothesis”, where the cause of demyelination is found either inside the CNS or 
outside of the CNS (Stys et al. 2012). The “inside-out” portion of the hypothesis 
suggests that a threat is detected within the CNS, causing CNS immune cells to 
signal to other immune cells outside of the CNS to cross the BBB and take part in 
demyelination. In contrast, the “outside-in” portion of the hypothesis suggests that 
reactive immune cells cross the BBB into the CNS and initiate demyelination. 
Regardless of how demyelination might have etiologically originated, common 
features are found in all MS patients, including inflammation, demyelination, and 
in certain cases, remyelination and CNS repair. In each of these stages, 
microglia, macrophages, and their immunological phenotype, have an important 
role to play.  
In the normal CNS environment, oligodendrocytes produce, wrap, and 
maintain myelin found along the axons of neurons. Two classes of distinct 
myeloid cells, blood-derived macrophages and CNS-resident microglia, survey 
the environment for either threats or damage. Both cells express similar cell 
markers, making it difficult to distinguish between them pathologically and/or 
immunohistochemically. In this quiescent environment with no perceived threats 
or damage, microglia and blood-derived macrophages are in a “resting” 
immunological phenotype. Although not strictly “resting”, these myeloid cells 
constantly survey their environment. Microglia exhibit a ramified phenotype with 
extended processes to monitor signals from their environment for any change in 
homeostasis, and to respond quickly (Nimmerjahn et al. 2005). Blood-derived 
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macrophages originate as circulating monocytes in the blood, and can move into 
other tissues, such as the brain or spinal cord, during inflammatory episodes 
(Serbina et al. 2008; Shi and Pamer 2011). 
During inflammatory conditions, macrophages and microglia receive 
certain stimuli that alter their phenotype and function. In the literature, a proposed 
classification of the various phenotypes of macrophages and microglia is the 
M0/M1/M2 classification (Fairweather and Cihakova 2009; Franco and 
Fernández-Suárez 2015; Mantovani et al. 2004; Martinez et al. 2009; Martinez et 
al. 2008; Michell-Robinson et al. 2015), Although this is a helpful and simplified 
classification of phenotypes, activation states of macrophage and microglia likely 
exist in a spectrum or combination of phenotypes in vivo. M0 is considered to be 
a “resting” phenotype and they are non-activated/non-polarized (Chistiakov et al. 
2018; Michell-Robinson et al. 2015) . M1 polarization, also known as “classical” 
activation, arises when either macrophages or microglia are cultured with 
lipopolysaccharide (LPS) and/or interferon-! (IFN!). This phenotype is 
considered to be pro-inflammatory. M1-polarized macrophages or microglia 
characteristically release pro-inflammatory cytokines/chemokines (e.g. tumour 
necrosis factor (TNF), interleukin-12 (IL-12), CXCL8-11, CXCL13) and reactive 
oxygen species (ROS) (Fairweather and Cihakova 2009; Mantovani et al. 2004) 
and limit growth factor and nutrient availability to cells infected with pathogens 
(Fairweather and Cihakova 2009). In contrast, M2 polarization, also known as 
“alternative” activation, is considered to be an “anti-inflammatory” phenotype and 
is characterized by their involvement with the elimination of parasites, promoting 
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angiogenesis, and cell/tissue regeneration (reviewed in (Franco and Fernández-
Suárez 2015)). M2 cells can be further classified into M2a, M2b, M2c, (and M2d 
for macrophages) as described in the literature (Franco and Fernández-Suárez 
2015; Michell-Robinson et al. 2015), and can be polarized in vitro in the presence 
of interleukin-4 (IL-4), interleukin-10 (IL-10), IL-13, or transforming growth factor 
β (TGFβ) (Franco and Fernández-Suárez 2015; Michell-Robinson et al. 2015).  
In MS, during immune surveillance, the CNS-targeted immune response 
becomes triggered and involves a complex pathophysiology. The following are 
common characteristics found in MS pathology, and it is important to note that 
these may occur simultaneously and not strictly in this order of events. First, the 
BBB shows signs of leakage in MRI studies (Cramer et al. 2014; McFarland et al. 
1992). Second, T cells, B cells, and monocytes/macrophages cross the BBB into 
the CNS (Larochelle et al. 2011), whereby monocytes become activated and 
differentiate into macrophages (Brück et al. 1995). Third, there is evidence of 
either loss, death, or damage to oligodendrocytes, oligodendrocyte progenitor or 
precursor cells (OPCs), and neurons, as well as demyelination (Kuhlmann et al. 
2002; Lucchinetti et al. 1999; Trapp et al. 1998).  
Macrophages and microglia participate in the demyelination process by 
destroying myelin, acting as antigen presenting cells to naïve T and B cells, 
cause oxidative damage to tissue, and release pro-inflammatory cytokines. 
Evidence for these behaviours during MS pathology are supported in the 
following studies. Increased numbers of activated macrophages/microglia appear 
 8 
in lesions (Brück et al. 1995; Ferguson et al. 1997) and near axons (Trapp et al. 
1998). Although four distinct patterns of MS lesions may develop, all include 
evidence of microglia/macrophage participation (Lucchinetti et al. 2000). 
Furthermore, it has been suggested that microglia may initiate demyelination in 
humans (Gay et al. 1997), and there is evidence of macrophages ingesting 
myelin in early and active MS lesions (Newcombe et al. 1994; van Horssen et al. 
2008). Moreover, in vitro, rat and human microglia are capable of ingesting 
myelin fragments (Chastain et al. 2011; Smith 1993; Williams et al. 1994). In 
active demyelinating MS lesions, both microglia and blood-derived macrophages 
express major histocompatibility complex (MHC) class II antigens (Bö et al. 
1994b; Boyle and McGeer 1990; Cuzner et al. 1988; Hayes et al. 1988), 
suggesting that they may be involved in antigen presentation to T cells during 
demyelination. In MS, there is also evidence to suggest that microglia and blood-
derived macrophages may contribute to tissue damage by releasing reactive 
oxygen species. For example, there is evidence to suggest that in initial MS 
lesions, activated microglia and macrophages may be a source of ROS, which 
could contribute to oxidative injury (Fischer et al. 2012). In another example, 
nitrotyrosine, a biochemical marker for peroxynitrite (Cross et al. 1998) (a 
chemical generated by nitric oxide reacting with superoxide, capable of damaging 
cells and tissue (Cross et al. 1998)), is found in human MS brains (Bagasra et al. 
1995; Cross et al. 1998; Hooper et al. 1997) and there is evidence to suggest it 
may have originated from macrophages/microglia expressing inducible nitric 
oxide synthase (iNOS) (Bagasra et al. 1995; Hooper et al. 1997). An increase in 
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myeloperoxidase (an enzyme that catalyzes the production of the highly cytotoxic 
hypochlorous acid (Gray et al. 2008b; Minohara et al. 2006; Spickett et al. 2000)) 
by macrophages/microglia is evident in white matter (Gray et al. 2008b) and 
cerebral cortex (Gray et al. 2008a) in MS, and is associated with demyelination. 
Oxidative damage within human neurons, oligodendrocytes, and myelin is 
evident in MS (Fischer et al. 2013; Haider et al. 2011). In addition to oxidative 
damage, there is also parallel pro-inflammatory cytokine modulation, including 
increased TNF and interleukin-6 (IL-6) cytokine/mRNA expression (Cannella and 
Raine 1995; Maimone et al. 1997; Schönrock et al. 2000; Selmaj et al. 1991; 
Woodroofe and Cuzner 1993). Several studies have identified 
macrophages/microglia as a source of TNF and IL-6 within active lesions 
(Cannella and Raine 1995; Selmaj et al. 1991; Woodroofe and Cuzner 1993). 
This production and release of reactive oxygen species, effective antigen-
presentation capacity, and pro-inflammatory cytokine production by 
macrophages/microglia during demyelination in MS, are all characteristics of the 
pro-inflammatory M1 phenotype (Durafourt et al. 2012; Franco and Fernández-
Suárez 2015; Sica et al. 2015).  
Following active demyelinating episodes, neurons may degrade due to 
glutamate excitotoxicity (Pitt et al. 2000), axonal transection (Trapp et al. 1998), 
Wallerian degeneration (Dziedzic et al. 2010), or due to ion imbalances such as 
sodium or calcium imbalances (Smith 2007). Remyelinating a damaged myelin 
sheath will occur if the damage is worth expending an appropriate amount of 
energy versus allowing the neuron/axon itself to degrade. Remyelination is the 
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production of myelin sheaths by newly differentiated oligodendrocytes; these new 
sheaths form “shadow” plaques (as evidenced through MRI). Remyelination is 
important for recovery because it improves both electrical conduction and 
communication (Smith et al. 1979; Smith et al. 1981), saves demyelinated 
neurons from deterioration (Irvine and Blakemore 2008), and recovers motor 
deficits (Jeffery and Blakemore 1997; Murray et al. 2001). In humans, there is 
evidence that the degree of spontaneous remyelination can be considerable in 
MS patients (Barkhof et al. 2003; Goldschmidt et al. 2009; Patani et al. 2007; 
Patrikios et al. 2006), however, the extent of remyelination diminishes with 
disease progression (Goldschmidt et al. 2009). 
The remyelination of axons is a simple solution in theory, but it is 
challenging to implement, as it requires three general conditions (Chandran et al. 
2008; Franklin and ffrench-Constant 2008). First, following the demyelinating 
episode, the environment must be cleared of both axonal and myelin 
fragments/debris. Second, remyelination requires an influx and/or presence of 
oligodendrocyte progenitor cells (OPCs). Finally, OPCs recruited and existing 
within the demyelinated area need to successfully differentiate into myelin-
producing oligodendrocytes that eventually remyelinate neurons. Failing to 
achieve any of these conditions will result in remyelination failure.  
The key to meeting these criteria for remyelination may be encouraging the 
transition of pro-inflammatory “M1” myeloid cells towards an anti-inflammatory 
“M2” phenotype that encourages repair. Indeed, there is evidence that this 
transition tends to occur during remyelination. In an in vivo lysolecithin 
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demyelination model in mice, a transition from a M1 to a M2 phenotype in 
microglia and macrophages is observed at the beginning of remyelination (Miron 
et al. 2013). In MS cases, most macrophages/microglia expressed M1 markers in 
active demyelinating MS lesions, and a portion of those macrophages/microglia 
also expressed M2 markers, and so those cells expressing both M1 and M2 
markers were considered to be in an intermediate activation state (Vogel et al. 
2013); in a later study, there was evidence of microglia exhibiting an intermediate 
activation state by expressing markers for both M1 and M2 in preactive and 
remyelinating lesions (Peferoen et al. 2015), This may suggest a majority of cells 
are “M1-like” during active demyelination, while in remyelination, more cells shift 
toward an “M2-like” state, expressing both markers for M1 and M2. To further 
explain how the transition from an M1 to M2 phenotype in myeloid cells is 
important for remyelination, evidence for each of the remyelination challenges will 
be briefly discussed, along with evidence that the M1 to M2 transition could help 
address that challenge (Chandran et al. 2008; Franklin and ffrench-Constant 
2008). 
1.2.1 Remyelination and the M1 to M2 Shift in Macrophages/Microglia in 
MS 
 
To begin, the first requirement for remyelination is that the CNS 
environment must be cleared of both axonal and myelin debris/fragments 
(Chandran et al. 2008; Franklin and ffrench-Constant 2008). In vivo, myelin 
fragments impair remyelination (Kotter et al. 2006) and prevents the 
differentiation of OPCs if they are not removed (Kotter et al. 2006; Robinson and 
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Miller 1999). Cells that are capable of removing this debris include 
microglia/macrophages, and they can achieve this by phagocytosing the debris. 
Evidence for this includes the observation of microglia phagocytosing cellular and 
myelin debris in a mouse cuprizone demyelination model (Olah et al. 2012), and 
the observation that remyelination becomes impaired if the phagocytic ability of 
macrophages/microglia becomes impaired (Lampron et al. 2015; Natrajan et al. 
2015). A transition from an M1 to an M2 phenotype in microglia/macrophage 
polarization could encourage the phagocytosis of myelin/cellular debris, as M2-
polarized microglia/macrophages are more phagocytic compared to their M1 
counterparts (Durafourt et al. 2012), and therefore could remove more debris 
than M1-polarized myeloid cells.  
Second, remyelination require an influx and/or presence of OPCs near the 
demyelinated area (Chandran et al. 2008; Franklin and ffrench-Constant 2008). 
Evidence for this comes from the fact that post-mitotic oligodendroytes do not 
contribute to remyelination in rats (Keirstead and Blakemore 1997). Instead, in 
rodents, neural stem cells (NSCs) and/or OPCs travel to demyelinated lesions 
and contribute to remyelination (Di Bello et al. 1999; Xing et al. 2014). 
Furthermore, in mice, the number of OPCs from SVZ progenitors increase near 
demyelinated lesions in surrounding white matter (Nait-Oumesmar et al. 1999; 
Picard-Riera et al. 2002). A similar observation was also seen in MS, when OPC 
numbers increase in the human SVZ in response to demyelination (Nait-
Oumesmar et al. 2007). The transition from M1 myeloid cells to an M2 phenotype 
could encourage successful OPC recruitment. In a study by Choi et al. (Choi et 
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al. 2017) supernatants from M2-polarized BV-2 microglia encouraged neural 
stem/progenitor cell proliferation in the SVZ in ex vivo cultures. Although there is 
some evidence to suggest that M1 macrophages may encourage more 
movement of stem cells in the injured CNS in mice than M2 macrophages (Zhang 
et al. 2015), I argue that these cells would need to eventually polarize towards an 
M2 phenotype, as there is evidence that M2 cells encourage OPC differentiation 
(Butovsky et al. 2006; Choi et al. 2017; Miron et al. 2013; Moore et al. 2015; 
Zhang et al. 2015), the third requirement for remyelination.  
Third, remyelination requires the successful differentiation of OPCs into 
myelinating oligodendrocytes (Chandran et al. 2008; Franklin and ffrench-
Constant 2008). In MS, there is evidence that OPCs are successfully recruited to 
lesions but fail to differentiate into myelinating oligodendrocytes (Kuhlmann et al. 
2008; Wolswijk 1998). A transition from M1 to M2 polarized 
microglia/macrophages could help address this problem. In rodent models, 
studies found that M2-polarized microglia or macrophages significantly increased 
oligodendrogenesis from stem/progenitor cells compared to controls than M1-
polarized cells in vitro (Butovsky et al. 2006; Choi et al. 2017; Miron et al. 2013; 
Zhang et al. 2015). In addition, depleting M2-polarized macrophages/microglia in 
a demyelinated lesion hindered OPC differentiation and delayed remyelination in 
vivo, while depleting M1-polarized macrophages/microglia did not hinder 
remyelination (Miron et al. 2013). Supernatants from human M1 blood-derived 
macrophages and microglia were cytotoxic to human A2B5+ neural progenitors 
and reduced galactocerebroside and O4+ oligodendrocyte lineage cells in vitro, 
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while supernatant from human M2 polarized cells had little to no effect (Moore et 
al. 2015). Therefore, the data suggests that M1-polarized cells may hinder 
oligodendrogenesis, while M2 cells may maintain or promote oligodendrogenesis. 
1.2.2 Neurogenesis, Neuron Recovery, and M1 to M2 Polarization 
 
 Not only is remyelination helpful in MS, but neurogenesis can also play a 
part in recovery. Indeed, there is evidence that neurogenesis is possible in 
chronic white matter lesions of MS (Chang et al. 2008). Similar to remyelination, 
there is evidence that the transition from M1 to M2 polarization in 
microglia/macrophages is beneficial for neurogenesis and neuron recovery. For 
example, in mice, the presence of M1-polarized microglia inhibited the survival of 
mouse neurons (Kobayashi et al. 2015). In addition, the presence of 
supernatants from M1-polarized microglia/macrophages was associated with 
reduced neurogenesis from mouse neural stem cells compared to M2 polarized 
cells (Butovsky et al. 2006; Choi et al. 2017; Zhang et al. 2015). Furthermore, 
neurites in vitro can regrow more efficiently following the removal of axonal debris 
(Tanaka et al. 2009), and so it is possible that M2 myeloid cells, which are more 
phagocytic than their M1 counterparts (Durafourt et al. 2012), could encourage 
efficient debris clearance and lead to neurite regrowth. 
1.2.3 Treatment for MS 
 
 To encourage remyelination and recovery in MS, the development of novel 
treatments is paramount. Current treatments include rehabilitation and 
modulating/suppressing the immune response through medication (Miller 2012); 
 15 
however, there is evidence to suggest that the applicability of 
immunomodulatory/immunosuppressive drugs to chronic and progressive forms 
of MS is limited (Larochelle et al. 2016), which is most likely due to a significant 
neurodegenerative component at this stage of disease. Developing new drugs for 
MS is complicated by the fact that there is a low clinical trial success rate when 
translating results from rodent experiments (Baker and Amor 2015). Stem cell 
therapy is also being investigated to treat MS (Meamar et al. 2016), although they 
do not address all three conditions necessary for remyelination. Theoretically, an 
optimal treatment would need to focus on addressing all conditions necessary for 
remyelination. Encouraging myeloid cells to transition from M1 to M2 phenotype 
may serve as a clinically relevant and viable approach, which could be achieved 
using microRNAs.  
1.3 MicroRNAs in Disease and MS 
MicroRNAs (or miRNAs) are small, non-coding ribonucleic acids (RNAs) 
that are approximately 18-22 nucleotides in length (Rodriguez et al. 2004). First 
discovered in 1993 (Lee et al. 1993), microRNAs are believed to regulate many 
biological processes. It is estimated that greater than 60% of human genes are 
conserved microRNA targets (Friedman et al. 2009), and as of February 2015, 
there are approximately 2,800 human microRNAs described in public repositories 
(Londin et al. 2015). In addition, microRNAs are highly conserved across species, 
highlighting their important regulatory functions (Bartel 2004; Lagos-Quintana et 
al. 2001; Lau et al. 2001; Lee and Ambros 2001). It is believed that if a microRNA 
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is expressed, it inhibits the production of its target protein by targeting its mRNA, 
which decreases the amount of protein available for its downstream functions 
(Guo et al. 2010). 
In the linear canonical microRNA processing pathway, beginning in the 
nucleus of the cell, the gene or intron of mammalian microRNAs are first 
transcribed by RNA polymerase II or III to produce the primary-microRNA (pri-
miRNA), the microRNA transcript. The pri-miRNA is further cut by the Drosha-
DiGeorge critical region 8 (Drosha-DGCR8) microprocessor complex into the 
precursor microRNA (pre-miRNA), a hairpin structure which moves outside of the 
nucleus into the cytoplasm by the transporter Exportin-5-Ran-guanosine 
triphosphate (Exportin-5-Ran-GTP). The transactivation response ribonucleic 
acid-binding protein (TRBP) with the Dicer enzyme further cuts the “loop” end of 
the pre-miRNA, creating the -3p and -5p mature microRNAs. The Argonaute-2 
(Ago2) protein then binds to the mature microRNA, creating the ribonucleic acid-
induced silencing complex (RISC). The RISC with the mature microRNA then 
binds to target mRNAs, which can induce either translational repression, 
cleavage, or deadenylation (Bartel 2004; Winter et al. 2009). Figure 1 
summarizes this process.   
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Figure 1: Biogenesis of MicroRNAs 
 
MicroRNAs are initially transcribed by RNA polymerase II or III, generating 
primary microRNAs (pri-miRNA) with hairpin structures. Pri-miRNAs are further 
processed by the Drosha-DGCR8 microprocessor complex to produce pre-
microRNAs. Pre-microRNAs are exported from the nucleus into the cytosol by 
Exportin-5-Ran-GTP. In the cytosol, pre-miRNAs are cleaved by the 
ribonucleases Dicer and transactivation response RNA-binding protein (TRBP), 
and form mature microRNAs that are recruited to the RNA-induced silencing 
complex (RISC) where they come in contact with their target mRNAs and the 
Argonaute-2 (Ago2) protein. Mature microRNAs bind target mRNAs via a short 
seed sequence (6-8mer) that is located at their 5` end. The binding of the miRNA 
to its targeted mRNA results in either degradation of the mRNA transcript or it is 
recycled back into the cytoplasm. Alternatively, miRNAs can be actively released 
into the extracellular space (via microvesicles & exosomes) and be transported to 
neighbouring cells (Bartel 2004; Winter et al. 2009; Zampetaki et al. 2012). 
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Figure 1. Bioge esis of microRNAs. MicroRNAs are initially transcribed by RNA polymerase II (RNAPol 
II), generating primary microRNAs (pri-MicroRNA) with hairpin structures. Pri-MicroRNAs are further 
processed by the ribonucleases Drosha and Pasha to produce pre-MicroRNAs. Pre-MicroRNAs are 
exported from the nucleus into the cytosol by the proteins Exportin, Ran, and GTP. In the cytosol, pre-
MicroRNAs are cleaved by the ribonucleases Dicer and transactivation response RNA-binding protein 
(TRBP), and form mature microRNAs that are recruited to the RNA-induc d silencing compl x (RISC) 
where they come in contact with their target mRNAs and the Argonaute2 (Argo2) protein. Mature 
microRNAs bind target mRNAs via a short seed sequence (6-8mer) that is located at their 5` end. As a 
general rule, the greater number of base pairs in the seed sequence, the more effective the microRNA is at 
blocking protein translation. The binding of the microRNA to its targeted mRNA results in either 
degradation (via the proteasome) or it is recycled. Alternatively, micro As can also be packaged in 
microvesicles/exosomes and transported outside the cell, where they can be trafficked to neighbouring 
cells.
<1";+2,6()*
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Since their discovery, dysregulated microRNA expression has been 
suggested to contribute to disease development. Whether found in abnormally 
high or low concentrations, dysregulated microRNAs could also serve as 
diagnostic biomarkers for disease. Their potential as biomarkers arises from the 
fact that circulating microRNAs are relatively stable and resistant to RNAse 
degradation, potentially due to being encapsulated in microvesicles or non-
vesicle associated microRNA-protein/lipoprotein complexes (Zampetaki et al. 
2012). MicroRNAs have been identified as potential biomarkers in many cancers, 
including prostate (Mitchell et al. 2008), ovarian (Häusler et al. 2010), breast 
(Schrauder et al. 2012), and lung (Patnaik et al. 2012). MicroRNAs may also 
serve as potential biomarkers in immune-mediated diseases such as rheumatoid 
arthritis (Pauley et al. 2008) and MS (Gandhi 2015). Not only can dysregulated 
microRNAs potentially be used to diagnose disease, they may also be amenable 
to therapeutic manipulation, which has led to the field of microRNA therapeutics. 
Notably, in different animal cancer models, Garo and Murugaiyan (Garo and 
Murugaiyan 2016) highlight several papers outlining microRNA target-specific 
technology that have shown potential in curing disease with few or no side-effects 
(Babar et al. 2012; Chen et al. 2010; Huang et al. 2013; Wu et al. 2013). 
MicroRNA therapeutics are therefore an exciting and relatively new field of 
biomedical research that could be instrumental in curing disease.  
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1.4 MicroRNA-146a 
MiR-146a is a member of the miR-146 family, of which there are two 
types: miR-146a and miR-146b. MiR-146a is found on human chromosome 5 
within the non-coding RNA host gene MIR3142HG (chromosome 5q33.3) 
(Paterson and Kriegel 2017). To date, miR-146a is known to play a role in innate 
immunity, inflammation, and cancer (Paterson and Kriegel 2017); however, it may 
also have a role in adaptive immunity (Lu et al. 2010). In humans, besides MS 
(Lescher et al. 2012), miR-146a is associated with other diseases, including 
rheumatoid arthritis (Nakasa et al. 2008; Nakasa et al. 2011), prion disease 
(Saba et al. 2012), and sepsis (Zhou et al. 2015). MiR-146a is also associated 
with cancer development, including breast (Bhaumik et al. 2008), thyroid (He et 
al. 2005), and pancreatic (Li et al. 2010) cancer.  
In general, miR-146a is considered to have anti-inflammatory properties 
when expressed (Paterson and Kriegel 2017). There is evidence that miR-146a 
expression depends on NF-kB expression, and acts as a negative feedback 
regulator of NF-kB signalling by targeting pro-inflammatory genes, including 
tumour necrosis factor receptor-associated factor 6 (TRAF6) and interleukin-1 
receptor-associated kinase (IRAK1) (Taganov et al. 2006). Components derived 
from either bacteria (e.g. LPS) (Nahid et al. 2009) or viruses (Cameron et al. 
2008; Motsch et al. 2007; Tang et al. 2009) can induce miR-146a expression, 
and miR-146a has been associated with endotoxin tolerance (Doxaki et al. 2015; 
Nahid et al. 2009; Nahid et al. 2015). Furthermore, there is also evidence that 
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miR-146a is required for regulatory T cells to restrict IFN!-mediated pathogenic 
Type 1 T helper responses by targeting signal transducer and activator of 
transcription 1 (STAT1) in regulatory T cells (Lu et al. 2010). MiR-146a knockout 
mice have a hyperresponsive immune response, where knockout mice produced 
more pro-inflammatory cytokines in blood serum compared to wild-type after LPS 
injection, and BMDMs from knockout mice produced more pro-inflammatory 
cytokines compared to wild type after exposure to LPS (Boldin et al. 2011). 
Furthermore, miR-146a-null mice experienced massive myeloproliferation, and 
aged mice experienced features suggestive of autoimmune disease and tumours 
as they aged with multi-organ inflammation compared to controls (Boldin et al. 
2011). This strongly suggested the role of miR-146a in preventing autoimmunity 
and tumour/myeloid cell development (Boldin et al. 2011). 
 MiR-146a expression may also be altered with age. In a study by Jiang et 
al. (Jiang et al. 2012), miR-146a levels in peritoneal macrophages from untreated 
aged mice were elevated compared to younger mice. However, the peritoneal 
macrophages from aged mice could not increase miR-146a levels as high as 
levels from peritoneal macrophages from younger mice when mice were injected 
with LPS, or when the peritoneal macrophages were exposed to pro-
inflammatory cytokines in culture (such as TNF or IL-6) (Jiang et al. 2012). 
Furthermore, elevated levels of miR-146a were found in mouse microglia when 
they were cultured in vitro for long periods of time compared to cells that were not 
cultured as long (Caldeira et al. 2014).  
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Although a majority of the literature describes miR-146a as anti-
inflammatory, there have been some studies that suggest otherwise, particularly 
in the context of Alzheimer’s disease. In a study by Cui et al. (Cui et al. 2010), 
miR-146a appeared to be associated with the downregulation of IRAK1 and 
upregulation of interleukin-1 receptor-associated kinase 2 (IRAK2) induced NF-
#B, which maintained a prolonged inflammatory response in human astroglial 
cells. There is also evidence that a repressor of brain inflammation, 
complimentary factor H, is a target of miR-146a (Lukiw et al. 2008). However, the 
evidence provided by Taganov et al. (Taganov et al. 2006) and Boldin et al. 
(Boldin et al. 2011) in animal knockout studies, provides more direct evidence 
that miR-146a works as a negative regulator of inflammation and halting myeloid 
development. Therefore, both studies offer more compelling evidence that miR-
146a, when expressed, is anti-inflammatory.  
1.4.1 MicroRNA-146a in MS 
 
MiR-146a is elevated in peripheral blood mononuclear cells (PBMCs) and 
CD14+ monocytes in the blood of RRMS patients compared to controls (Moore et 
al. 2013; Waschbisch et al. 2011). In progressive forms of MS, including both 
SPMS and PPMS, there is evidence that miR-146a levels are similar to controls 
(Fenoglio et al. 2011). In cerebrospinal fluid (CSF), Quintana et al. measured a 
downregulation of miR-146a levels in RRMS patients compared to other 
neurological disease controls (Quintana et al. 2017). Besides examining miR-
146a in blood and CSF, miR-146a alterations have also been examined in MS 
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brain tissue. There is evidence showing that miR-146a levels increased in active 
MS lesions and in the microvessels of MS-active lesions (Junker et al. 2009; Wu 
et al. 2015). This increase in miR-146a in human active lesions is also consistent 
with increased miR-146a levels found in active lesions in mouse and marmoset 
models of MS (Lescher et al. 2012).  
Recently, Moore et al. (Moore et al. 2013) measured miR-146a expression 
in CD68+ macrophages/microglia from the brain parenchyma of non-inflamed 
control tissue and in inflamed untreated MS lesions using laser-capture 
microdissection. There was a suggested decrease in miR-146a fold change 
expression in laser-captured CD68+ macrophages/microglia in the untreated MS 
brains compared to controls, although the sample size was small (n = 3 for 
control and n = 4 for MS patient) and the difference was not statistically 
significant at the time of publication (p = 0.264, unpaired t-test). This suggested 
decrease was not consistent with previous reports of increased miR-146a in 
active MS lesions (Junker et al. 2009; Wu et al. 2015), PBMCs (Fenoglio et al. 
2011; Waschbisch et al. 2011) and CD14+ monocytes from the blood in RRMS 
MS patients (Moore et al. 2013). Therefore, this potential inconsistency of miR-
146a levels in macrophages/microglia in the context of MS warranted further 
investigation. 
1.5 Thesis Hypothesis and Objectives  
Based on the recent finding by Moore et al. (Moore et al. 2013) in CD68+ 
macrophages/microglia in the brains of untreated MS patients, and the current 
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understanding of miR-146a and remyelination in MS, the following general 
hypothesis was proposed. During acute inflammation, myeloid cells are initially 
polarized toward an M1 pro-inflammatory phenotype and take part in 
demyelination in MS. As mentioned before, miR-146a is generally considered to 
be anti-inflammatory and functions as a negative regulator of inflammation 
(Boldin et al. 2011; Taganov et al. 2006). While M1 myeloid cells take part in 
demyelination, at the same time miR-146a levels naturally increase in these cells 
over time. As miR-146a increases over time, these pro-inflammatory M1 myeloid 
cells become less M1-like, and polarize towards an anti-inflammatory M2 
phenotype over time. As a result, the anti-inflammatory M2 myeloid cells take part 
in addressing the three criteria required for remyelination. This leads to repair and 
an eventual resolution of inflammation and disease activity. Having served its 
purpose as a negative regulator of inflammation, miR-146a naturally decreases in 
the M2 myeloid cells to homeostatic levels. 
Chronic CNS inflammation and an insufficient miR-146a expression within 
myeloid cells may promote disease activity. This theory is supported by the 
potential decrease of miR-146a in myeloid cells in untreated MS patients (Moore 
et al. 2013), and by the attenuation of miR-146a expression to pro-inflammatory 
stimuli in older mice compared to younger mice (Jiang et al. 2012). As a 
consequence, the M1 phenotype found in active demyelination in MS will 
dominate without hindrance by miR-146a. As a result, the M2 phenotype does 
not develop, leading to a failure to remyelinate, and thus the inflammation and 
disease activity does not resolve. Correspondingly, there is evidence that the 
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more chronic the MS disease, the less remyelination tends to occur (Goldschmidt 
et al. 2009). Finally, although speculative, one could postulate that decreased 
miR-146a in RRMS myeloid cells may signal the beginning of progressive 
disease towards SPMS, where higher levels of PBMC miR-146a were found in 
RRMS patients compared to controls, while PBMC miR-146a in SPMS and 
PPMS was similar to controls (Fenoglio et al. 2011). Based on this information, 
therapeutically elevating miR-146a expression in myeloid cells in chronic RRMS, 
SPMS, or PPMS patients may promote and maintain the tissue-repairing M2-like 
phenotype in myeloid cells, which is associated with remyelination and recovery. 
A visual outline of this overall hypothesis is described in Figure 2. 
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Figure 2: Overall hypothesis of the potential role of miR-146a in acute and 
chronic inflammation in multiple sclerosis 
  
A well-known function of miR-146a is its negative regulation of the pro-
inflammatory NF-#B pathway by inhibiting pro-inflammatory gene expression, 
such as IRAK1 and TRAF6 (Taganov et al. 2006). Based on a potentially lower 
miR-146a expression in primary human CD68+ macrophages/microglia in 
patients with untreated MS compared to controls (Moore et al. 2013), no 
significant rise in miR-146a compared to controls in PBMCs in patients with 
progressive forms of MS (Fenoglio et al. 2011), and a potentially attenuated miR-
146a response to pro-inflammatory stimuli in macrophages due to age (Jiang et 
al. 2012), the following hypothesis is proposed. During acute inflammation, miR-
146a levels naturally increase over time. The rise of miR-146a inhibits the 
expression of pro-inflammatory genes that are already highly expressed during 
the initial stages of inflammation. As a result, pro-inflammatory gene pathways 
(such as the NF-#B pathway), are inhibited, leading to a reduction and eventual 
resolution of inflammation. This could be described as being similar to a negative 
feedback loop. However, during chronic central nervous system inflammation, 
miR-146a levels may decrease over time. Since the availability of miR-146a is 
insufficient to bind to the higher amounts of mRNA of pro-inflammatory genes 
present, the mRNA of these genes continue to be translated, and inflammation 
continues without a resolution. This could be described as being similar to a 
positive feedback loop. To resolve chronic inflammation, therapeutically 
increasing and maintaining a sufficiently high expression of miR-146a may help 
to overcome the functional deficiencies of miR-146a in macrophages/microglia by 
inhibiting pro-inflammatory gene translation. 
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From this overall hypothesis, I formulated a more detailed hypothesis and 
generated aims to facilitate an investigation. I hypothesize that miR-146a 
upregulation in myeloid cells can shift a pro-inflammatory (M1) phenotype 
towards an anti-inflammatory (M2) phenotype, which will promote differentiation 
of neural stem cells to OPCs and neurons. The four aims of the study will use 
synthetically-made miR-146a mimic, as it is a cost-effective way to test the effect 
of endogenous miR-146a, compared to isolating enough miR-146a from living 
tissues for experimentation. The four aims include: 
Aim #1: Provide evidence that microRNAs can be transfected into primary 
mouse and human macrophages/microglia and human THP-1 
macrophages. 
To achieve Aim #1, each cell type will be treated in either of two ways. 
Cells will be transfected with a synthetic miR-146a mimic and miR-146a will be 
measured using the quantitative reverse transcription polymerase chain reaction 
(RT-qPCR) assay, or cells will be transfected with a fluorescently labelled 
microRNA, and the amount of microRNA transfected will be measured using flow 
cytometry.  
Aim #2: Analyze supernantants for production of pro-inflammatory cytokines from 
pro-inflammatory activated (M1) myeloid cells transfected with miR-
146a mimics. 
To achieve Aim #2, each cell type will be cultured in vitro and transfected 
with miR-146a mimic. Subsequently, cells will be polarized towards an M1 
phenotype using LPS, similar to the phenotype seen in active demyelination. 
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Supernantants derived from these cells will be analyzed for pro-inflammatory 
cytokine production relevant to MS. 
Aim #3: Validate miR-146a gene targets, inducible nitric oxide synthase (iNOS) 
and Ras homolog A (RhoA). 
To achieve Aim #3, predicted targets of miR-146a, iNOS and RhoA, will be 
examined on all cell types. iNOS and RhoA are both predicted targets of miR-
146a and are also associated with MS pathology. Cells will be transfected with 
miR-146a mimic, then stimulated with LPS, as mentioned previously. Following 
stimulation, cells will be collected and western blots will be used to examine iNOS 
and RhoA production in cells. 
Aim #4: Determine if miR-146a can indirectly influence OPC differentiation and 
neuron development in mice. 
 Finally, to determine if miR-146a can influence neurogenesis and 
oligodendrogenesis from neural stem cells, mouse bone marrow-derived 
macrophages (BMDMs) will first be treated with miR-146a mimic and stimulated 
with LPS. Next, supernatant from these cells will be cultured with mouse 
neurospheres. The total number of cells, neurons, OPCs, neurosphere area, the 
percentage of total cells that are either neurons or OPCs, and the density of 
neurons or OPCs, will be analyzed and normalized per neurosphere.  
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Chapter 2 - Methods and Materials 
2.1 Isolation and Culture of Animal Cells 
2.1.1 Isolation of Primary Mouse Bone Marrow-Derived Macrophages 
Primary BMDMs were isolated from wild-type C57BL/6 mice (Charles 
River) using a modified protocol by Ying et al. (Ying et al. 2013). Briefly, wild-type 
C57BL/6 mice from 6 weeks of age or older were euthanized by CO2. The body 
and fur were disinfected with 70% ethanol, and the hind limbs were removed. The 
muscle was carefully cut away from the bone, and the femur and tibia bones 
were separated. Separate petri dishes were used for each individual mouse 
preparation; instruments were sterilized between each dissection. For each femur 
and tibia, both ends were cut, and the marrow was ejected from the bone using a 
sterile 21 - 21 % gauge needle and 3mL of sterile phosphate-buffered saline 
(PBS, pH 7.4, 10mM PO4, 2.7mM KCl, 137mM NaCl, 1.76mM KH2PO4). The 
marrow was then either triturated using the needle 4-6 times and passed through 
either a 40uL or 70uL strainer, or ground in the strainers, to remove larger tissue 
and bone fragments. This ensured a preparation that was dissociated into single 
cells. Dishes, needles and strainers were rinsed with an additional 2mL of PBS 
and passed through the strainer to yield the maximal cell number. A 0.8% sterile 
ammonium chloride red blood cell lysis solution (pH 7.2-7.6) (University of 
Washington 2017) was added to 3 times the volume of the BMDM preparation to 
remove red blood cells, and this mixture was left on ice for 10 minutes. Then, the 
mixture was spun at 500 x g for 5 minutes at 4°C. The supernatant was 
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aspirated, and a BMDM growth media consisting of Dulbecco’s Modified Eagle 
Medium (DMEM) (Cat. #: 12100-046, Gibco, Life Technologies), 10% heat 
inactivated fetal bovine serum (HI FBS) (Cat. # 35-015-CV, USA Sourced, 
Corning, USA) or heat inactivated NuSerum IV (Cat. # 355500, Corning, USA), 
100 U/mL of penicillin and 100 g/mL of streptomycin (1x P/S) (Cat. # 15140122, 
Gibco, Life Technologies or Cat. #: P4333, Sigma-Aldrich) and 2mM of L-alanyl-
L-glutamine dipeptide (1X GlutaMAX) (Cat. # 35050-061, GlutaMAX, Gibco, Life 
Technologies) with 10ng/mL of recombinant human Macrophage Colony-
Stimulating Factor (M-CSF) (Cat. # 300-25, PeproTech) was added. Cells were 
counted, additional BMDM growth media was added to the cells to make the cell 
concentration 2 x 106 cells/mL, and cells were plated into 12- (2 x 106 cells/well) 
or 6-well (6 x 106 cells/well) tissue culture treated wells, marking Day 0. Cultures 
were grown at 37oC in 5% CO2. On Day 3, a half media change was performed 
using fresh media as described above. On Day 7-8, the cells were washed once 
with PBS prior to use. A typical picture of mouse BMDMs can be found in Figure 
3.  
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Figure 3: Examples of mouse and human cells successfully cultured in 
vitro  
 
(A) Primary mouse BMDMs. (B) Primary mouse microglia. (C) Primary mouse 
neurospheres. (D) Human THP-1 monocyte-derived macrophages. (E) Primary 
human fetal microglia. (F) Primary human adult microglia. Scale bar = 100µm.  
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2.1.2 Isolation of Primary Mouse Microglia 
Primary mouse microglia were isolated from a mouse mixed glial culture 
by mild trypsinization using a protocol by Saura et al. (Saura et al. 2003) with 
modification. Dissection solution (DS) consisted of Hank’s Balanced Salt Solution 
(Cat. # H8264, Sigma Life Science), 2mM of HEPES solution (Cat. # H0887, 
Sigma Life Science), and P/S. A portion of DS was pre-warmed into a 37°C water 
bath. A trypsin inhibitor solution consisting of 20% heat-inactivated (HI) FBS in 
DS was prepared, and placed in the 37°C water bath. Finally, astrocyte media 
consisting of DMEM, 10% HI FBS or HI NuSerum IV, P/S and GlutaMAX was 
prepared, and a portion was pre-warmed in the 37°C water bath. Throughout the 
whole procedure, separate instruments and solutions were used for each 
experimental group of cortices.  
Briefly, wild-type postnatal day 1 – postnatal day 6 (P1-P6) C57BL/6 
mouse pups were euthanized by decapitation and the brain was removed and 
placed into a sterile dish containing DS. The cortices were isolated and 
transferred into another clean sterile dish with DS. The meninges containing 
blood vessels were removed, and cortices were placed into another final clean 
sterile dish with DS. The cortices were then divided into smaller pieces using 
sterile forceps and washed with fresh DS. Then, per 6 mouse cortices, a solution 
containing 0.8% trypsin (Cat. # 15090-046,ThermoFisher Scientific) in DS with 
0.05mg/mL of DNase I (Cat. #11 284 932 001, Roche) was added. The cortices 
were then incubated at 37°C on a rotating Nutator for 17 minutes. Cortices were 
 32 
washed once with pre-warmed DS. Next, pre-warmed trypsin inhibitor was added 
and the cortices were incubated on a rotating Nutator at 37°C for another 10 
minutes to inhibit any remaining trypsin. Cortices were then washed with pre-
warmed astrocyte media, and then resuspended in 6mL of pre-warmed astrocyte 
media. Cortices were then triturated into a single cell suspension. The single cell 
suspension was then spun at 270 x g for 5 minutes at room temperature, 
supernantant was aspirated, and cells were resuspended in mixed glial culture 
media and plated in tissue-culture treated flasks. Mixed glial cultures were 
incubated at 37oC in 5% CO2. Media was replaced 1-2 days later, and every 4-16 
days after the initial media change as necessary. To collect mouse astrocyte 
conditioned media, media was collected from mixed culture during media 
changes, spun at 751 x g for 20 minutes, and the clean supernatant was 
collected and stored at either 4°C (for use within 7 days) or -80°C (for long-term 
storage). Once astrocytes were at least confluent for 3-5 days or more, the flasks 
were washed once with either PBS or serum-free defined media for 1 minute to 
remove residual serum. Trypsin-EDTA (Cat. # 15400-054, ThermoFisher 
Scientific) was diluted to 0.25% with PBS, and was added to serum free defined 
media at a ratio of 1:3. This was the “mild trypsin” solution. The mild trypsin 
solution was then added to the mixed glial culture for 20-30 minutes in the 
incubator at 37°C until the astrocyte layer peeled off. If necessary, the original 
flask was washed once with PBS to remove any residual astrocytes that 
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detached. A figure of the separation of mouse astrocytes and microglia is found 
in Figure 4. 
 
 
 34 
 
 
 
Figure 4: Separation of primary mouse astrocytes from mouse microglia 
using the modified mild trypsinization method  
 
To separate mouse microglia from mouse astrocytes in a mixed culture, the mild 
trypsinization method (Saura et al. 2003) with modification was used. Using this 
method, a highly confluent astrocyte layer (right) separates from the bottom of the 
flask, leaving a relatively pure population of mouse microglia still adhered to the 
flask (left). The microglia are then collected and replated. Scale bar = 500µm. 
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 Diluted 0.25% trypsin-EDTA in PBS was then added to the microglia for 5-
15 minutes in the incubator, with an additional 2mM of EDTA if needed to recover 
a higher yield of microglia. Cells were vigorously pipetted and collected. Cells 
were centrifuged at 270 x g for 10 minutes at 4oC. Mouse microglia were then 
resuspended in mouse astrocyte-conditioned media, counted, resuspended at 1 x 
105 cells/mL, and plated into either 24-well (5 x 104 cells/well) or 12-well (1 x 105 
cells/well), or 6-well (3 x 105 cells/well) tissue culture treated plates in mouse 
astrocyte-conditioned media for 24 hours prior to experimentation. 
2.2 Isolation and Culture of Human Cells 
2.2.1 Culture of THP-1 Macrophages 
 
 THP-1 monocytes (Cat. # TIB-202TM, ATCC®) of passage <15 were 
cultured in complete Roswell Park Memorial Institute (RPMI) 1640 media (Cat. 
#R8758, Sigma-Aldrich) containing 10% HI FBS, P/S and GlutaMAX at 37oC in 
5% CO2. Monocytes were plated at 5 x 105 cells/mL in a 24-well plate (2.5 x 105 
cells/well) with complete media with 20ng/mL of phorbol 12-myristate 13-acetate 
(PMA) (Cat. # P8139, Sigma) for 24 hours for cells to adhere and differentiate 
into macrophages. After 24 hours cells were washed once with fresh complete 
media. 
2.2.2 Isolation of Primary Human Monocyte-Derived Macrophages 
 
Human monocyte-derived macrophages (MDMs) were isolated using a 
protocol as described in Moore et al. (Moore et al. 2013). All studies using human 
samples followed Canadian Institutes of Health Research guidelines and were 
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approved by the institutional review board at McGill University and Memorial 
University of Newfoundland (Health Research Ethics Authority). Briefly, 
peripheral blood was collected from healthy donors with informed consent. A 
Ficoll density gradient was used to isolate peripheral blood mononuclear cells 
(PBMCs) from whole blood. Briefly, blood from one individual was collected into a 
BD Vacutainer® vial, and 2 vials were poured into a 50mL centrifuge tube. Vials 
were rinsed with PBS and contents were added to the tube to collect as many 
cells as possible. The centrifuge tube was topped up to 35mL using PBS. A 60mL 
syringe with a spinal needle containing 15mL of Ficoll-Hypaque solution (Cat. # 
17-1440-03, GE Healthcare) was slowly added to the bottom of the 50mL 
centrifuge tube. The centrifuge tube was spun at 609 x g for 30 minutes without 
the brake. When the centrifuge came to a complete stop, the plasma (top layer) 
was removed, and the middle white buffy layer (PBMCs) were pipetted and 
placed into another 50mL tube. PBMCs were washed once by topping up the 
tube to 50mL with PBS, inverting the tube to mix, and centrifuging the tube at 423 
x g for 15 minutes with the brake. The supernatant was poured off, and the tube 
was scratched against a grated surface to resuspend the pellet. The pellet (or 2 
pellets combined from the same individual if another tube was being processed at 
the same time) were placed into one 50mL centrifuge tube, and the volume was 
brought up to 50mL using PBS. The tube was spun at 270 x g for 10 minutes. 
Supernatant was poured off and the tube was scratched against a grated surface 
to resuspend the pellet. All PBMC pellets from the individual were pooled into one 
50mL centrifuge tube. To further isolate CD14+ cells from the PBMC population, 
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anti-CD14 immunomagnetic microbeads (Miltenyi Biotec, Auburn, CA) were used 
following the manufacturer’s instructions, resulting in a CD14+ monocyte 
population of 95-98% purity.  
 CD14+ monocytes were subsequently plated at a density of 5 x 105 
cells/mL in RPMI 1640 media containing 10% HI FBS, P/S and GlutaMAX at 
37oC in 5% CO2 in 12-well (5 x 105 cells/well) and 6-well (1.5 x 106 cells/well) 
tissue-culture treated plates. MDMs were obtained by culturing the monocytes 
with M-CSF (25ng/mL) over 5 days.   
2.2.3 Isolation of Primary Human Fetal and Adult Microglia 
 
Human fetal and adult microglia were isolated in a similar manner as 
outlined in Moore et al. (Moore et al. 2013). All studies using human samples 
followed Canadian Institutes of Health Research guidelines, and were approved 
by the institutional review board at McGill University and Memorial University of 
Newfoundland (Health Research Ethics Authority).  
Briefly, human fetal CNS tissue was obtained from either consenting 
donors (Health Sciences Centre – General Hospital, St. John’s, NL), from 
Novogenix Laboratories (Torrance, CA, USA), or from a human fetal tissue 
repository (Albert Einstein College of Medicine, Bronx, USA). Brain tissue from 
the temporal lobe of patients undergoing surgery for non-tumour-related 
intractable epilepsy was used to isolate human adult microglia. Brain tissue within 
the suspected focal area was not used. Human fetal and adult microglia cells 
were isolated and cultured as described previously (Durafourt et al. 2013; Moore 
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et al. 2013). Once fetal and adult microglia were isolated, they were plated at 1 x 
105 cells/mL in 12-well (1 x 105 cells/well) and 6-well (3 x 105 cells/well) tissue 
culture treated plates. 
2.3 MicroRNA Transfection, LPS Stimulation, and Collection of 
Supernatant 
 
For transfection of negative control and miR-146a microRNAs into all cell 
types, Lipofectamine® RNAiMAX Transfection Reagent (Cat. # 13778-100, 
Invitrogen, Life Technologies) was used according to the manufacturer’s 
instructions. For mouse cells and THP-1 macrophages, mirVanaTM miRNA mimic 
Negative Control #1 (Cat. # 4464058, Ambion) and hsa-miR-146a-5p mirVanaTM 
miRNA mimic (Cat. # 4464066, mature miRNA sequence: 
UGAGAACUGAAUUCCAUGGGUU, Ambion) were used for transfection. For 
human MDMs, human fetal microglia, and human adult microglia, miR-146a 
mimic (Cat. #: C-300630-03-0002, hsa-miR-146a-5p, associated mature miRNA: 
UGAGAACUGAAUUCCAUGGGUU, Dharmacon) and negative control (Cat. #: 
CN-001000-01-05, Based on cel-miR-67, mature sequence: 
UCACAACCUCCUAGAAAGAGUAGA, Dharmacon) were used for transfection. 
Lipofectamine was diluted 1:100 in serum-free DMEM, P/S and GlutaMAX 
(considered as the vehicle mixture). Then, miRNA controls and mimics were 
added to the corresponding vehicle mixture and left to equilibrate for 20-30 
minutes at room temperature. Before transfection, mouse BMDMs and human 
microglia and MDMs were washed once with PBS. Human THP-1 macrophages 
were washed once with complete media before transfection. 
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Primary mouse microglia were transfected for 24 hours. Primary mouse 
bone-marrow-derived macrophages were transfected for 48 hours. THP-1 
macrophages and primary human monocyte-derived macrophages were 
transfected for 72 hours. Primary human microglia were transfected for 72 hours. 
Previous optimization experiments for transfection of microRNAs in primary 
human MDMs and microglia were conducted by Moore et al. using this procedure 
(Moore et al. 2013). 
Following transfection of human MDMs and microglia, cells were washed 
once with PBS. THP-1 macrophages were washed once with complete media 
after transfection. Next, either complete media or complete media containing 
lipopolysaccharide (100ng/mL, Cat. # L 5024, serotype O127:B8, Sigma) was 
added to the appropriate wells for 6 hours. Following transfection for mouse 
BMDMs and microglia, no PBS wash was conducted to avoid losing cells. 
Instead, the original transfection media was removed and replaced with either 
complete media for the “No Treatment” experimental group or complete media 
containing lipopolysaccharide to the other experimental groups for 6 hours. 
After 6 hours, the supernatant was collected on ice. Clean supernatant 
was obtained by centrifuging at 500-700 x g for 10 minutes at 4oC to separate 
cellular debris, and the clean supernatant was stored at -80oC. 
2.4 Flow Cytometry 
 To evaluate microRNA transfection efficiency using Lipofectamine 
RNAiMAX in THP-1 macrophages, THP-1 macrophages were developed as 
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described above in a 24-well plate, plated at 5 x 105 cells/mL (2.5 x 105 
cells/well). THP-1 macrophages were divided into two groups: untreated cells, 
and cells transfected with 30nM of Cy3-labelled microRNA (Cy3TM Dye-Labelled 
Anti-miRTM Negative Control #1, Cat. #: AM17011, Invitrogen, ThermoFisher 
Scientific) using Lipofectamine RNAiMAX as described above. Cells were 
transfected for 48 hours. After 48 hours of transfection, cells were scraped in 
PBS, spun for 5 minutes at 270 x g, washed 1x in fluorescence-activated cell 
sorting (FACS) buffer (1% Bovine Serum Albumin (BSA) (Cat. # A9647-100G, 
Sigma) in PBS) and resuspended in FACS buffer. Data was acquired using a 
FACSCalibur flow cytometer (BD Biosciences), and analyzed using FlowJo 
software V.10.0.8 (FlowJo, LLC, Ashland, Oregon, USA).  
2.5 RNA Isolation, Preamplification Polymerase Chain Reaction, and 
Quantitative Polymerase Chain Reaction 
 
At the end of each experiment, cells were washed with PBS and TRIzol® 
Reagent (Cat. # 15596018, Ambion by Life Technologies) or QIAzol® Lysis 
Reagent (Cat. # 79306, QIAGEN) was added directly to wells.  RNA was 
extracted according to the manufacturer’s protocol. RNA concentration was 
determined on a Nanodrop 1000 Spectrophotometer (Thermo Scientific). 
Reverse transcription was performed using the TaqMan® MicroRNA Reverse 
Transcription Kit (Cat. # 4366597 and Cat. # 4366596, Applied Biosystems) 
according to the manufacturer’s protocol. Polymerase chain reaction (PCR) was 
conducted with the Taqman® Universal PCR Master Mix (Cat. # 4304437, 
Applied Biosystems) (Hold at 95°C for 10min, and then 40 cycles of 95°C for 15 
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seconds to 60°C for 1min). Probes and primers used were hsa-miR-146a-5p 
(Cat. # 4427975, TaqmanTM MicroRNA Assays, ThermoFisher Scientific), RNU48 
(Cat. # 4427975, TaqmanTM MicroRNA Control Assays, ThermoFisher), and 
SNO202 (Cat. # 4427975, TaqmanTM MicroRNA Control Assays, ThermoFisher 
Scientific or Cat. # CCU001S, ThermoFisher Scientific). RT-qPCR was read on 
an Applied Biosystems® ViiA 7 Real-Time PCR System and analysis was 
conducted on QuantStudioTM Software by Applied Biosystems. Minus reverse 
transcriptase and no-template cDNA controls were included. Fold changes were 
calculated using the 2-&&CT method (Livak and Schmittgen 2001; Schmittgen and 
Livak 2008).  
2.6 Western Blotting  
At the end of the experiment, cells were placed on ice. Supernatant was 
removed, then either sodium dodecyl sulphate (SDS) sample buffer (10% w/v 
glycerol, 5% v/v "-mercaptoethanol, 2.3% w/v SDS, 0.0625M Tris pH 6.8, 0.1-
0.2% bromophenol blue, overall pH 6.8) or standard radioimmunoprecipitation 
assay (RIPA) buffer (10mM Tris-Cl (pH 8.0), 1mM EDTA, 1% Triton X-100, 0.1% 
sodium deoxycholate, 0.1% SDS, 140mM NaCl) with 1mM Na3VO4 and BD 
Baculogold protease inhibitors (BD Biosciences) were added to each well. The 
wells was scraped, and the contents were collected into a 1.5mL eppendorf tube, 
vortexed, and placed into -80oC for later use. Protein concentration was 
determined by using the Total Protein Kit, Micro Lowry, Peterson’s Modification 
(Cat. # TP0300-1KT, Sigma Aldrich), measuring readings using Genesys 10uv 
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Scanning (Thermo Scientific) or by using the PierceTM Bicinchoninic Acid (BCA) 
Protein Assay Kit (Cat. # 23227, Thermo), measuring readings using the 
CytationTM 5 Cell Imaging Multi-Mode Reader (BioTek).  
All western blots were developed in the following procedure. Briefly, 
equivalent amounts of protein were loaded into wells of a gel, along with 
prestained markers (PageRule Prestained Protein Ladder, Cat. # 26616, Thermo 
Scientific or MagicMark XP Western Protein Standard, Cat. # LC5602, 
ThermoFisher Scientific). The gel was run at 180V until the bands and ladder 
passed through the gel, and then the proteins were transferred to a 
polyvinylidene difluoride membrane (PVDF). The membrane was blocked in 5% 
milk/phosphate-buffered saline with Triton X (0.3%) (PBST) for 1 hour at room 
temperature on a shaker. Primary antibodies in 5% milk/PBST with 0.02% NaN3 
were added to the membrane and shaken overnight at 4"C. Afterwards, the 
membrane was washed three times for 5 minutes each in PBST, and the 
appropriate IgG antibody conjugated to the horseradish peroxidase enzyme (IgG-
HRP) in 5% milk/PBST was added to the membrane and shaken for 1 hour at 
room temperature. Afterwards, the membrane was washed three times for 5 
minutes each in PBST. Detection was achieved using the Pierce Enhanced 
Chemiluminescence (ECL) Western Blotting Substrate (Cat. #: 32106, Thermo 
Scientific), and blots were exposed to x-ray film and developed. Densitometry 
was conducted as a form of semi-quantification using ImageJ (version 1.51w), 
(Schindelin et al. 2015; Schneider et al. 2012), and the densitometry procedure is 
outlined in Appendix A, based on information and tutorials from the ImageJ User 
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Guide – IJ 1.46r (Ferreira and Rasband 2012), Luke Miller (Miller 2010), and Tim 
Starr (Starr 2013) with modification. 
If the blot needed to be stripped to test for actin, the following was 
performed. Briefly, the blot was washed three times for five minutes each in 
PBST. Stripping buffer that was made in the lab (0.0625M Tris, pH 7.2, 2% SDS, 
0.007% #-Mercaptoethanol in deionized water) was added to cover the blot, and 
incubated at 60"C in a water bath for 30 minutes. The membrane was then 
washed three times for 5 minutes each in PBST, and reblocked in 5% milk/PBST 
for 1 hour at room temperature on a shaker or overnight on a shaker at 4"C. 
Then, the membrane was reprobed for actin using the procedure mentioned 
above.  
The western blot examining iNOS in mouse BMDMs had 40ug of protein 
for each sample, and the samples were run on a gradient gel (Cat. # 
NW04122BOX, BoltTM 4-12% Bis-Tris Plus Gels, Invitrogen). The primary 
antibody that was used was anti-iNOS (2ug/mL (1:26), Cat. # ab15323, rabbit 
polyclonal antibody, Abcam), and the secondary antibody that was used was goat 
anti-rabbit IgG-HRP (1:2000, Cat. # sc-2004, Santa Cruz). The blot was then 
stripped and probed for actin as described above. For testing actin, the primary 
antibody that was used was anti-actin (1:1000, Cat. # A4700, mouse monoclonal 
antibody, Sigma), and the secondary antibody that was used was goat anti-
mouse IgG-HRP (1:2000, Cat. # sc-2005, Santa Cruz Biotechnology). 
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The western blot examining RhoA in mouse BMDMs had 40ug of protein 
for each sample, and the samples were run on a gradient gel (Cat. # 
NW04122BOX, BoltTM 4-12% Bis-Tris Plus Gels, Invitrogen). The primary 
antibody that was used was anti-RhoA (26C4) (1:200, Cat. # sc-418, mouse 
monoclonal antibody, Santa Cruz Biotechnology), and the secondary antibody 
that was used was goat anti-mouse IgG-HRP (1:2000, Cat. # sc-2005, Santa 
Cruz Biotechnology). The blot was then stripped and probed for actin as 
described above. For testing actin, the primary antibody that was used was anti-
actin (1:1000, Cat. # A4700, mouse monoclonal antibody, Sigma), then the 
secondary antibody that was used was goat anti-mouse IgG-HRP (1:2000, Cat. # 
sc-2005, Santa Cruz Biotechnology). 
The western blot examining human MDM iNOS had 10ug of protein for 
each sample, and the samples were run on a 10% 1mm acrylamide gel made in 
the lab. For efficient probing without the need to strip the blot, the blot was cut 
into two, dividing the protein of interest from the actin loading control. Each 
portion was processed separately. For the iNOS portion, the primary antibody 
that was used was anti-iNOS (1:500, Cat. # NB300-605SS, rabbit polyclonal 
antibody, Novus Biologicals), and the secondary antibody that was used was 
goat anti-rabbit IgG-HRP (1:2000, Cat. # sc-2004, Santa Cruz). For the actin 
portion, the primary antibody that was used was anti-actin (1:1000, Cat. # A4700, 
mouse monoclonal antibody, Sigma), and the secondary antibody that was used 
was goat anti-mouse IgG-HRP (1:2000, Cat. # sc-2005, Santa Cruz 
Biotechnology). 
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The western blot examining human MDM RhoA had 10ug of protein in 
each sample, and the samples were run on a 10% 1mm acrylamide gel made in 
the lab. For efficient probing without the need to strip the blot, the blot was cut 
into two, dividing the protein of interest from the actin loading control. Each 
portion was processed separately. For the RhoA portion, the primary antibody 
that was used was anti-RhoA (26C4) (1:200, Cat. # sc-418, mouse monoclonal 
antibody, Santa Cruz Biotechnology), and the secondary antibody that was used 
was goat anti-mouse IgG-HRP (1:2000, Cat. # sc-2005, Santa Cruz 
Biotechnology). For the actin portion, the primary antibody that was used was 
anti-actin (1:1000, Cat. # A4700, mouse monoclonal antibody, Sigma), and the 
secondary antibody that was used was goat anti-mouse IgG-HRP (1:2000, Cat. # 
sc-2005, Santa Cruz Biotechnology). 
The western blot examining human Microglia iNOS had 20ug of protein in 
each sample, and the samples were run on a 10% 1mm acrylamide gel made in 
the lab. For efficient probing without the need to strip the blot, the blot was cut 
into two, dividing the protein of interest from the actin loading control. Each 
portion was processed separately. For the iNOS portion, the primary antibody 
that was used was anti-iNOS (1:500, Cat. # NB300-605SS, rabbit polyclonal 
antibody, Novus Biologicals), and the secondary antibody that was used was 
goat anti-rabbit IgG-HRP (1:2000, Cat. # sc-2004, Santa Cruz Biotechnology). 
For the actin portion, the primary antibody that was used was anti-actin (1:1000, 
Cat. # A4700, mouse monoclonal antibody, Sigma), and the secondary antibody 
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that was used was goat anti-mouse IgG-HRP (1:2000, Cat. # sc-2005, Santa 
Cruz Biotechnology). 
The western blot examining human microglia RhoA had 10ug of protein in 
each sample, and the samples were run on a 10% 1mm acrylamide gel made in 
the lab. For efficient probing without the need to strip the blot, the blot was cut 
into two, dividing the protein of interest from the actin loading control. Each 
portion was processed separately. For the RhoA portion, the primary antibody 
that was used was anti-RhoA (26C4) (1:200, Cat. # sc-418, mouse monoclonal 
antibody, Santa Cruz Biotechnology), and the secondary antibody that was used 
was goat anti-mouse IgG-HRP (1:2000, Cat. # sc-2005, Santa Cruz 
Biotechnology). For the actin portion, the primary antibody that was used was 
anti-actin (1:1000, Cat. # A4700, mouse monoclonal antibody, Sigma), and the 
secondary antibody that was used was goat anti-mouse IgG-HRP (1:2000, Cat. # 
sc-2005, Santa Cruz Biotechnology). 
Ponceau S solution (Cat. # P7170-1L, Sigma) was used to further identify 
relative actin concentrations on blots, following the manufacturer’s instructions. 
2.7 Enzyme-Linked Immunosorbent Assay 
Human tumour necrosis factor (TNF) (Cat. # 555212) and interleukin-6  
(IL-6) (Cat. # 555220), and mouse TNF (Mono/Mono) (Cat. # 555268) and IL-6 
(Cat. # 555240) OptEIA enzyme-linked immunosorbent assay (ELISA) kits were 
used from BD Biosciences, and performed according to the manufacturer’s 
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instructions. Absorbance readings were obtained using a CytationTM 5 Cell 
Imaging Multi-Mode Reader by BioTek. 
2.8 Microscopy of Mouse and Human Myeloid Cells 
Pictures of living cell cultures were taken on an Inverted Microscope for 
Cell and Tissue Culture Leica DMi1 (Leica Microsystems CMS GmbH). 
2.9 Analysis of Indirect Effect of miR-146a Transfected Cells on 
Neurosphere Development  
2.9.1 Mouse Neurosphere Culture 
 
Mouse neurospheres were isolated from wild-type C57BL/6 pups using a 
modified protocol from Moore et al. (Moore et al. 2011). Briefly, 24-48 hours after 
plating the mixed glial cultures from P1-P7 pups using the same procedure as 
described above, the media from the culture was removed and fresh media was 
added to the adhered cells. The media that was removed was centrifuged at 270 
x g for 10 minutes at room temperature. If needed, a 40uL strainer was used to 
avoid any clumping of cells. The supernatant was aspirated, and the pellet was 
resuspended in an equivalent amount of PBS or more to remove traces of serum 
and centrifuged for an additional 10 minutes. The PBS was aspirated off of the 
pellet, and the pellet was resuspended in mouse neurosphere growth media. For 
neurospheres used to count neurons, this media consisted of serum-free 
DMEM/Nutrient Mixture F-12 Ham (Cat. # D8437, Gibco, Life Technologies) with 
P/S and GlutaMAX, 20ng/mL of human recombinant basic fibroblast growth factor 
2 (FGF-2) (Cat. # F0291, Sigma-Aldrich), 10ng/mL of mouse epidermal growth 
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factor (EGF) (Cat. # E4127, Sigma), 1x B27 supplement without vitamin A (Cat. # 
12587, Life Technologies). For neurospheres used to count OPCs, media was 
the same as above, with the addition of 2ng/mL of filter-sterilized heparin (Cat. # 
H3149-10KU, Sigma-Aldrich). All neurospheres were then cultured in 6-well non-
tissue culture treated plates.  
As neurospheres grew in suspension in the 6-well non-tissue culture 
treated plates, they were lightly triturated as necessary to avoid clumping until a 
majority of spheres had grown to approximately 500µm to 1000µm in diameter (7 
days). An image of a growing neurosphere can be found in Figure 3. After 7 days, 
neurospheres were collected, divided into tubes equalling the number of 
experimental groups, spun at 200 x g for 4 mins at 4°C, the supernatant was 
removed, and neurospheres were mixed with serum-containing supernantant 
from conditioned mouse BMDMs. For neurospheres used to count OPCs, 1x N1 
supplement (Cat. # N6530-5ML, Sigma-Aldrich) was mixed with the BMDM 
supernatant.  
For neurospheres used to count neurons, neurospheres adhered and 
differentiated in 24 well plates with sterile laminin-coated coverslips. For 
neurospheres used to count OPCs, neurospheres adhered and differentiated in 
the wells of a NuncTM Lab-TekTM Chamber Slide System permanox slide (Cat. # 
177445, Thermo-Fisher Scientific). In the presence of serum contained in the 
supernatant, all neurospheres adhered to the bottom of the well and differentiated 
for a maximum of 7 days. A typical example of neurosphere development is seen 
in Figure 5.
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Figure 5: Primary mouse neurosphere development in vitro 
 
Murine-derived neurospheres were grown to approximately 500-1000µm in 
diameter (7 days). At this stage, neurospheres were cultured in the presence of 
supernatants derived from mouse BMDMs and their associated experimental 
conditions. At this stage, in the presence of FBS, the neurospheres immediately 
adhered to the wells and differentiated into astrocytes, neurons, and OPCs for a 
maximum of 7 days. Scale bar = 500µm. 
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2.9.2 Immunocytochemistry of Mouse Neurospheres  
Once neurospheres differentiated after 7 days, the cells were washed 
once with PBS, fixed with 4% paraformaldehyde (PFA) for 5 minutes at room 
temperature, and washed twice with PBS before storage in PBS at 4oC until 
staining.  
2.9.2.1 Immunocytochemistry of Mouse Neurospheres for Neurons 
 
For mouse neurospheres used to count for neurons, cells were 
permeabilized and blocked using PBST with 10% normal goat serum (NGS) for 
0.5 hours at room temperature. Then, anti-"III-Tubulin (1:500, Cat. #801201, 
Mouse IgG2a, BioLegend) with 1% NGS in PBST was added and left overnight at 
4°C. Then, cells were washed 3x with PBS, 5 minutes each, and secondary 
antibody (1:1000, Cat. # A11005, Alexa Fluor® 594 goat anti-mouse IgG, Life 
Technologies) was added with 1% NGS in PBS for blocking for one hour at room 
temperature. Cells were washed 3x with PBS, 5 minutes each, and DAPI (1:1000 
in PBS, Cat. #: D1306, Invitrogen, ThermoFisher Scientific) was used to stain 
nuclei for 5 minutes, and then cells were washed for 15 minutes in PBS, then 
washed 3x in PBS for five minutes each. Laminin-coated discs were then 
mounted onto slides with fluoromount gel (Cat. #: 0100-1, Fluoromount-G®, 
SouthernBiotech) and stored at 4°C. 
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2.9.2.2 Immunocytochemistry of Mouse Neurospheres for OPCs 
 
For mouse neurospheres used to count for OPCs, cells were 
permeabilized and blocked using PBST with 10% NGS and 2% horse serum 
(blocking solution) for 0.5 hours at room temperature. Then, neural/glial antigen 2 
(NG2) primary antibody (1:500 in blocking solution, Cat. # AB5320, rabbit 
polyclonal antibody EMD Millipore) was incubated with slides for 1 hour at room 
temperature. Cells were washed twice with PBS, then incubated with 10% NGS, 
2% horse serum, and PBS with secondary antibody (1:1000, Alexa Fluor® 594 
goat anti-rabbit IgG Cat. # A11012, Life Technologies) for 1 hour at room 
temperature. Then, cells were washed once with PBS and DAPI (1:1000, Cat. #: 
D1306, Invitrogen, ThermoFisher Scientific) for 2 minutes, washed briefly with 
PBS alone, coverslipped using flouromount-G, then stored at 4°C. 
Immunocytochemistry for mouse OPCs was conducted by Dylan Galloway. 
2.9.3 Image Analysis 
For neurospheres used to count neurons, images were taken on a Carl 
Zeiss inverted microscope Axio Observer.Z1 (Zeiss) and used the accompanying 
Zen 2 (blue edition) software (Zeiss). For neurospheres used to count OPCs, 
images were taken on the CytationTM 5 Cell Imaging Multi-Mode Reader (BioTek) 
and used the accompanying Gen5 software (BioTek). All images were captured 
by a blinded observer. Similar microscopy settings were maintained across all 
images. Three representative neurospheres were taken for each experimental 
group. For ease in distinguishing neurospheres for either neuron or OPC 
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counting, "III-tubulin+ cells in this thesis are coloured red, while NG2+ cells in 
this thesis are coloured green (colors edited from channel .tif file using Fiji). 
The images for neurospheres were analyzed using Fiji (Version 2.0.0-rc-
49/1.51a) for Mac (Schindelin et al. 2012; Schindelin et al. 2015; Schneider et al. 
2012). The specific settings used in the macro (or program), written in the “IJ1 
Macro” language, can be found in the program code in Appendix B. Briefly, the 
DAPI and "III-Tubulin or NG2 channels of the neurosphere image are saved as 
separate .tif files. These files are then blinded to the researcher for counting. 
First, the DAPI and "III-Tubulin/NG2 images are manually adjusted in Fiji to 
clearly see nuclei and the perimeter of the neurosphere. Next, using the Fiji 
selection tool, selections of the center (using the adjusted nuclei image) and 
perimeter of the neurosphere (using the adjusted neuron image) are saved. Next, 
using a written macro for Fiji, all original channel images are automatically 
adjusted for brightness and contrast. The DAPI image is processed further. 
Background noise is subtracted, a set threshold on nuclei size is set, the white 
nuclei are turned black on a white background, and the nuclei are automatically 
divided up into individual particles by the “Convert To Mask” and “Watershed” 
programs in Fiji. Next, the center of the neurosphere and the outside of the 
neurosphere are eliminated by automatically overlaying the center and perimeter 
.roi files, leaving a ring of nuclei. The nuclei in this ring are then counted and 
tallied using the “Analyze Particles” program in Fiji. The outlines of each nuclei 
that the program counts are saved for later. Finally, channel images with 
automatically adjusted brightness and contrast are merged: nuclei and neurons 
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or OPCs. For each merged image, one more is made with the overlay of the 
counted nuclei by the macro. After the images are made, the number of "III-
tubulin+ or NG2+ cells from the cells with circled nuclei, and the total area of the 
neurosphere, is counted and measured by a blinded researcher. Figure 6 outlines 
this entire procedure. Figure 7 and Figure 8 outline the final neurosphere pictures 
created by the program for neurons and OPCs, respectively.
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Figure 6: Overview of image analysis for mouse neurospheres  
 
A detailed explanation of the image processing of mouse neurospheres is found 
in the Materials and Methods section. (Part 1) Channel images of each 
neurosphere were saved separately. Using Fiji, each channel image was 
manually adjusted for BC to see structures clearly, and outlines and centers of 
the neurosphere were created manually and saved. (Part 2a) Using the program, 
the original channel images were automatically adjusted for BC. The nuclei 
(DAPI) image was processed further to automatically count the number of nuclei, 
and create a separate image outlining which nuclei were counted. (Part 2b) For 
each neurosphere, all channel images are merged together and two final images 
are created: one with, and one without, the outlines of nuclei counted by the 
program. (Part 3) With the two final images, numbers of neurons or OPCs from 
the counted nuclei are counted manually. The total neurosphere area is 
measured using the area of the outline selection of the neurosphere in Fiji. (BC = 
Brightness and Contrast). 
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Figure 7: Mouse neurosphere processed using Fiji to count neurons  
 
(A) "III-Tubulin+ (neuron) staining. (B) DAPI+ (nuclei) staining. (C) Merging of 
"III-Tubulin+ and DAPI+ staining. (D) Merging of "III-Tubulin+ and DAPI+ 
staining, with the outlined nuclei in yellow by the program, and the perimeter 
selection created manually by the researcher in cyan. (E) A magnified area of 
image D with one example of a neuron. The yellow outline of nuclei with numbers 
is the overlay created by the program. (F) Identical area shown in image E 
without the counted nuclei overlay, showing the same neuron that was counted. 
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Figure 8: Mouse neurosphere processed using Fiji to count OPCs  
 
(A) NG2+ (OPC) staining. (B) DAPI+ (nuclei) staining. (C) Merging of NG2+ and 
DAPI+ staining. (D) A magnified area of image C with one example of an OPC. 
(E) Merging of NG2+ and DAPI+ staining, with the outlined nuclei in yellow by the 
program, and the perimeter selection created manually by the researcher in cyan. 
(F) A magnified area of image E with one example of an OPC counted as part of 
the nuclei counted by the program. The yellow outline of nuclei with numbers is 
the overlay created by the program (one outline with #9 in center on OPC). (G) 
Identical area shown in image E without the counted nuclei overlay, showing the 
same OPC that was counted. 
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2.10 Myelin Phagocytosis Assay  
 
The myelin phagocytosis assay using primary mouse microglia followed the 
procedure outlined in Durafourt et al. (Durafourt et al. 2012) with modification. 
Whole mouse brain myelin was isolated using an earlier protocol (Norton and 
Poduslo 1973) with modification. Briefly, white matter from whole brains of 
C57BL/6 mice were mechanically homogenized in 0.32M sucrose. To isolate 
myelin, the homogenized white matter underwent repeated sucrose density 
centrifugation and osmotic shocks. Primary mouse microglia were isolated using 
the mild trypsinization method as described above, and placed into the 8-well 
permanox chamber slides. Mouse microglia were either untreated, treated with 
30nM of negative control mimic, or treated with 30nM of miR-146a mimic for 48 
hours as described above. Then, 25µg/mL of isolated myelin was added to the 
cells for 24 hours. After 24 hours, the cells were fixed with 4% PFA for 15 
minutes at room temperature. Primary antibodies against myelin basic protein 
(MBP) (1:200, Cat. # 808401, Mouse IgG2b, BioLegend) and ionized calcium-
binding adapter molecule 1 (Iba1) (1:500, Cat. # 019-19741, Anti-Iba1, Rabbit, 
Wako) were added overnight at 4°C, and secondary antibodies at 1:1000 (Cat. # 
A11005, Alexa Fluor® 594 goat anti-mouse IgG, Life Technologies, Cat. # 
A11008, Alexa Fluor® 488 goat anti-rabbit IgG, Life Technologies) for 1 hour at 
room temperature. In a double-blind experiment, pictures were taken of each 
treatment group from multiple fields of view (5-10) and counted. The average 
percentage of myelin positive cells from all pictures of each treatment well was 
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calculated and graphed. All work pertaining to the phagocytosis assay and the 
subsequent immunohistochemistry and cell counting for the phagocytosis assay 
was conducted by Dylan Galloway. 
2.11 Statistical Analysis 
Statistical analyses were performed using GraphPad Prism Version 6.0g. 
Data is presented as mean +/- standard error of the mean. One-way analysis of 
variance was conducted, and the particular post hoc test used is mentioned in the 
figure description. p<0.05 was considered significant.
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Chapter 3 - Results 
3.1 Proof of MicroRNA Transfection 
3.1.1 MiR-146a mimic can be successfully transfected into primary mouse 
BMDMs and primary mouse microglia using Lipofectamine RNAiMAX 
 
To determine if a miR-146a mimic could be successfully transfected into 
primary mouse BMDMs and microglia, RT-qPCR was performed for miR-146a 
following transfection and LPS stimulation. LPS stimulation alone had a negligible 
effect on miR-146a expression compared to untreated cells (not shown). 
Elevated miR-146a expression was measured in both cell types compared to the 
negative control (Figure 9). The data suggests that primary mouse BMDMs 
transfected with 10nM and 30nM of a miR-146a mimic can have a higher 
expression of miR-146a compared to cells transfected with a negative control 
mimic (30nM). Similar results were also observed in primary mouse microglia. 
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Figure 9: Transfection of miR-146a mimic into primary mouse BMDMs and 
microglia using Lipofectamine RNAiMAX  
 
RT-qPCR probing for miR-146a expression was performed on primary mouse 
BMDMs and microglia that were untreated, treated with 30nM of NC miRNA with 
LPS stimulation, and either 0.1nM, 1nM, 10nM, and 30nM miR-146a mimic with 
LPS stimulation. LPS stimulation alone had a negligible effect on miR-146a fold 
change compared to untreated cells (not shown). (A) Amplification plot of miR-
146a mimic on a representative technical set of primary mouse BMDMs. (B) Fold 
change of miR-146a mimic in primary mouse BMDMs using the 2-&&CT method. 
(C) Amplification plot of miR-146a mimic on a representative technical set of 
primary mouse microglia. (D) Fold change of miR-146a expression in primary 
mouse microglia using the 2-&&CT method. n = 1 for primary mouse BMDMs and 
primary mouse microglia in technical duplicate.  
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3.1.2 MicroRNAs can be successfully transfected into human THP-1 
macrophages using Lipofectamine RNAiMAX 
 
To provide evidence for the successful transfection of a miR-146a mimic 
into human THP-1 macrophages, Cy3-labelled microRNA (30nM) was 
transfected into THP-1 macrophages for 48 hours. The mean fluorescence 
intensity of the labeled microRNA was measured using flow cytometry. 
Compared to untransfected cells, a higher fluorescent signal was detected in 
cells transfected with Cy3-labelled microRNA (Figure 10), suggesting that 
microRNAs can be successfully transfected with microRNAs. 
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Figure 10: MicroRNA mimics can be successfully transfected into THP-1 
macrophages using Lipofectamine RNAiMAX 
 
To provide evidence that microRNAs can be successfully transfected into THP-1 
macrophages, THP-1 macrophages were either untreated or transfected with a 
Cy3-labelled microRNA for 48 hours. The cells were subsequently collected and 
analyzed using flow cytometry. (A) Collection of THP-1 macrophages that were 
not transfected. (B) Collection of THP-1 macrophages that were transfected with 
the Cy3-labeled microRNA. In images A and B, the cells were gated identically. 
(C) Histogram of number of gated cells counted versus the recorded Cy3 signal 
for both untransfected and Cy3-transfected cells. There is a higher shift in the 
Cy3 signal from cells transfected with Cy3-microRNA compared to those that 
were untreated. n = 1 for THP-1 macrophages.
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3.2 Assessing Inflammatory Response of Primary Mouse Myeloid 
Cells Transfected with a MiR-146a Mimic 
3.2.1 ELISAs  
3.2.1.1 TNF production decreases in LPS-stimulated primary mouse 
BMDMs transfected with a miR-146a mimic  
 
A statistically significant decrease in TNF (Figure 11 A), but not IL-6 
(Figure 11 B) production was measured in mouse BMDMs that were transfected 
with 30nM of miR-146a mimic with LPS stimulation compared to the negative 
control.
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Figure 11: MiR-146a significantly decreases TNF in primary mouse BMDMs 
and IL-6 in primary mouse microglia after 6 hours under M1-polarizing 
conditions 
 
(A) Compared to the negative control, miR-146a mimic significantly decreased 
TNF production by primary mouse BMDMs that were transfected with 30nM of 
miR-146a mimic with LPS stimulation. (B) Compared to the negative control, 
miR-146a mimic did not significantly decrease IL-6 production by primary mouse 
BMDMs in any of the cells treated with miR-146a mimic with LPS stimulation. In 
the first experiment using primary mouse microglia, the initial result suggested 
that miR-146a, compared to the negative control, could significantly decrease 
TNF (C) and IL-6 (D) production in these cells. However, when the experiment 
was repeated, IL-6 (F), but not TNF (E), was significantly reduced by 30nM of 
miR-146a mimic with LPS stimulation compared to the negative control. All data 
is normalized as a percentage of the LPS Only response for each mouse 
experiment. Error bars represent the mean +/- standard error of the mean of 
independent experiments. One-way analysis of variance with Dunnett’s post hoc 
test was used to determine group differences. *p<0.05, ***p<0.001 compared to 
30nM NC microRNA mimic with LPS stimulation. (A) n = 4-5, (B) n = 4-5, (C) n = 
1, (D) n = 1, (E) n = 5, (F) n = 5.
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3.2.1.2 IL-6 production decreases in LPS-stimulated primary mouse 
microglia transfected with a miR-146a mimic  
 
A preliminary experiment using primary mouse microglia and a range of 
miR-146a mimic concentrations (1-30nM) suggested that LPS-stimulated cells 
transfected with 30nM may reduce TNF (Figure 11 C) and IL-6 production (Figure 
11 D) the most compared to the negative control, and the other miR-146a mimic 
concentrations. Additional experiments were then performed in four independent 
sets of primary microglia, and a statistically significant decrease in IL-6 
production (Figure 11 F) was observed. No statistically significant decrease was 
observed for TNF (Figure 11 E).  
3.2.2 Western Blots 
3.2.2.1 iNOS expression may increase upon LPS stimulation, but may not 
change in LPS-stimulated primary mouse BMDMs transfected with a 
miR-146a mimic  
 
While a possible increase in iNOS levels was observed upon LPS 
stimulation alone, iNOS expression (Figure 12 A and B) may not differ in primary 
mouse BMDMs that were treated with either a miR-146a mimic or negative 
control mimic. 
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Figure 12: MiR-146a may decrease RhoA, but not iNOS, in primary mouse 
BMDMs after 6 hours under M1-polarizing conditions 
 
(A) iNOS blot for primary mouse BMDMs. (B) Graph of relative densities of iNOS 
bands in A. No iNOS band was clearly detected under no treatment conditions; 
however, upon stimulation with LPS, a stronger iNOS band was observed. 
Although the data suggests miR-146a decreased iNOS production compared to 
the negative control, both were higher than the LPS Only control. (C) RhoA blot 
for primary mouse BMDMs. (D) Graph of relative densities of RhoA bands in C. 
The data suggests that RhoA in LPS-stimulated cells transfected with a miR-146a 
mimic (30nM) may decrease compared to the negative control, LPS only control, 
and untreated cells. Both blots used the same samples. n = 1.   
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3.2.2.2 RhoA expression may decrease in LPS-stimulated primary mouse 
BMDMs transfected with a miR-146a mimic  
 
In primary mouse BMDMs, RhoA expression (Figure 12 C and D) may 
decrease in LPS-stimulated cells transfected with a miR-146a mimic (30nM) 
compared to all other treatment groups, including untreated cells, LPS only, and 
LPS-stimulated cells transfected with a negative control mimic (30nM).  
3.3 Assessing Inflammatory Response of Human Myeloid Cells 
Transfected with a MiR-146a Mimic 
3.3.1 ELISAs 
3.3.1.1 TNF and IL-6 production may decrease in LPS-stimulated THP-1 
macrophages transfected with a miR-146a mimic  
 
For technical reasons, including the validation of microRNA transfection 
and its expected results (as previously documented in the literature), initial 
experiments were performed in the THP-1 cell line (n = 1) prior to applying 
methodologies in primary human myeloid cells. A suggested decrease in both 
TNF and IL-6 production was measured in THP-1 macrophages that were 
transfected with a miR-146a mimic (10nM & 30nM) compared to the negative 
control (30nM) (Figure 13). 
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Figure 13: MiR-146a may decrease TNF and IL-6 production by THP-1 
macrophages after 6 hours under M1-polarizing conditions  
 
Compared to the negative control, there was a suggested decrease in TNF (A) 
and IL-6 (B) production in LPS-stimulated THP-1 macrophages that were 
transfected with either 10nM or 30nM of miR-146a mimic. All data was 
normalized as a percentage of the average LPS Only response. Error bars 
represent the mean +/- standard error of the mean of technical replicates. n = 1 
performed in technical duplicate.
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3.3.1.2 TNF production decreases in LPS-stimulated primary human MDMs 
transfected with a miR-146a mimic  
 
A statistically significant decrease in TNF production was measured in 
LPS-stimulated primary human MDMs transfected with a miR-146a mimic (30nM) 
compared to control (Figure 14 A). No statistically significant difference in IL-6 
production was observed (Figure 14 B).  
3.3.1.3 TNF production may decrease in LPS-stimulated primary human 
fetal microglia transfected with a miR-146a mimic 
 
TNF production may decrease in LPS-stimulated primary human fetal 
microglia transfected with a miR-146a mimic (1nM) compared to controls; 
however, due to a small sample size at this time (n = 2 – 4), the current result 
was not statistically significant (Figure 14 C). There was potentially no difference 
in IL-6 production using the current sample size (n = 1 – 3) (Figure 14 D).  
3.3.1.4 TNF production may decrease in LPS-stimulated primary human 
adult microglia transfected with a miR-146a mimic  
 
TNF production may decrease in LPS-stimulated primary human adult 
microglia transfected with a miR-146a mimic (1nM, 10nM, and 30nM) compared 
to control mimic; however, due to a small sample size (n = 1 – 2), the result was 
not statistically significant at this time (Figure 14 E). There was potentially no 
difference in IL-6 production using the current sample size (n = 1 – 2) (Figure 14 
F). 
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Figure 14: MiR-146a may decrease TNF, but not IL-6, in primary human 
monocyte-derived macrophages, fetal microglia, and adult microglia, after 6 
hours under M1-polarizing conditions 
 
MiR-146a mimic (30nM) significantly decreased TNF (A), but not IL-6 (B), 
production by human MDMs after LPS stimulation, compared to the negative 
control (n = 5 for A and B). At this time, miR-146a may reduce TNF production 
(C) by human fetal microglia after stimulation with LPS compared to the negative 
control (n = 2 - 4), whereas miR-146a may not affect IL-6 production (D) after 
LPS stimulation (n = 1 – 3). In human adult microglia, miR-146a may potentially 
reduce TNF (E), but not IL-6 (F), production when cells are stimulated with LPS, 
compared to the LPS Only and/or the negative control (n = 1 – 2 for E, n = 1 – 2 
for F). All data was normalized as a percentage of the LPS Only response for 
each experiment. Error bars represent the mean +/- standard error of the mean of 
independent experiments. One-way analysis of variance with Dunnett’s post hoc 
test was used to determine group differences. *p<0.05 compared to 30nM of NC 
microRNA Mimic with LPS stimulation.  
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3.3.2 Western Blots 
3.3.2.1 iNOS expression may not change in LPS-stimulated primary human 
MDMs transfected with miR-146a mimic  
 
The western blot probed for iNOS using primary humans MDMs suggests 
that there may be no difference in iNOS expression between LPS-stimulated 
primary human MDMs transfected with a miR-146a mimic (0.1nM, 1nM, 10nM) 
compared to negative control microRNA mimic (30nM) (Figure 15 A and B).  
3.3.2.2 RhoA expression may decrease in LPS-stimulated primary human 
MDMs transfected with a miR-146a mimic  
 
Compared to cells treated with either LPS only or LPS-stimulated negative 
control microRNA mimic (30nM), RhoA may decrease in a dose-dependent 
manner in LPS-stimulated primary human MDMs transfected with miR-146a 
mimic (Figure 15 C and D).  
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Figure 15: MiR-146a may decrease RhoA, but not iNOS, in primary human 
MDMs after 6 hours under M1-polarizing conditions  
 
(A) iNOS blot for primary human MDMs. (B) Graph of relative densities of blots in 
A. The data suggests that iNOS expression by primary human MDMs treated with 
miR-146a mimic and LPS does not decrease compared to the negative control. 
(C) RhoA blot for primary human MDMs. (D) Graph of relative densities of RhoA 
bands in C. RhoA expression may decrease in primary human MDMs treated 
with 1nm, 10nM, and 30nM of miR-146a mimic with LPS stimulation compared to 
the 30nM NC miRNA mimic control, and the LPS only control. Both blots used the 
same samples. n = 1.
A B 
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3.3.2.3 iNOS expression may not change in LPS-stimulated primary human 
fetal microglia transfected with a miR-146a mimic  
 
Compared to no treatment, iNOS expression may increase upon LPS 
stimulation; however, among all LPS-stimulated cells, there may be no difference 
in iNOS expression (Figure 16 A and B).  
 
3.3.2.4 RhoA expression may not change in LPS-stimulated primary human 
fetal microglia transfected with miR-146a mimic  
 
Compared to LPS-stimulated cells transfected with a negative control 
microRNA mimic (10nM), there may be no difference in RhoA expression in LPS-
stimulated primary human fetal microglia transfected with a miR-146a mimic 
(0.1nM, 1nM, 10nM, 30nM) (Figure 16 C and D).  
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Figure 16: MiR-146a may not alter iNOS or RhoA expression in primary 
human fetal microglia after 6 hours under M1-polarizing conditions 
 
(A) iNOS blot for primary human fetal microglia. (B) Graph of relative densities of 
iNOS bands in A. The data suggests that iNOS may increase to a similar degree 
in all treatment groups with LPS stimulation compared to untreated cells; 
however, there is potentially no difference in iNOS expression in cells treated with 
a miR-146a mimic compared to the negative control or to cells treated with LPS 
only. (C) RhoA blot for primary human fetal microglia. (D) Relative densities of 
RhoA bands in C. The data suggests that RhoA expression in cells transfected 
with miR-146a mimic with LPS stimulation may decrease compared to the no 
treatment and LPS only control; however, RhoA expression by cells treated with 
the various concentrations of miR-146a mimic with LPS stimulation may be 
similar to the RhoA expression found in cells treated with 10nM NC microRNA 
mimic with LPS stimulation. Both blots used the same samples. n = 1.
A B 
C D 
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3.4 Assessing Indirect Effect of Primary Mouse BMDMs Transfected 
with miR-146a Mimic and LPS Stimulation on Neural Stem Cell 
Development  
3.4.1 Supernatants derived from LPS-stimulated murine BMDMs 
transfected with a miR-146a mimic did not affect neurogenesis in 
vitro  
 
The supernantants applied to murine neurospheres were taken from 
experiments (LPS-stimulated BMDMs transfected with a miR-146a mimic) where 
a statistically significant decrease in TNF was measured (Figure 17 A). The 
supernatants included both samples from previous experiments (Figure 11 A) in 
addition to newly generated validated supernatants. To determine whether 
supernatants influenced the total number of cells within individual neurospheres, 
the total number of nuclei counted within each neurosphere by the program was 
tallied. No differences in the number of total nuclei were observed (Figure 17 B). 
To determine whether supernatants influenced the total number of neurons 
(defined by "III-Tubulin+ cells), the total number of neurons (from counted nuclei) 
within individual neurospheres was tallied. No statistically significant differences 
were measured across treatment groups (Figure 17 C). To determine whether a 
potential increase in neurogenesis was due to a mere increase in overall 
neurosphere size, the effect of the supernatants on individual neurosphere area 
was measured. No differences were observed using supernatants derived from 
the miR-146a mimic vs. negative control mimic (Figure 17 D). To normalize the 
total number of neurons per neurosphere, the number of "III-Tubulin+ cells was 
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Figure 17: Neurogenesis analysis from primary mouse neurospheres 
cultured with supernatant from miR-146a-transfected primary mouse 
BMDMs with M1-polarizing conditions   
 
The procedure for the neuron neurosphere assay is described in the Materials 
and Methods section. (A) In all neurosphere differentiation assays, all primary 
mouse BMDM supernantants derived from LPS-stimulated cells transfected with 
a mir-146a mimic had a statistically significant decrease in TNF levels compared 
to negative control (n = 5). (B) There is no statistically significant difference in the 
number of nuclei counted within a neurosphere between treatment groups. (C) 
There was no statistically significant difference between numbers of differentiated 
neurons grown in supernatants derived from LPS-stimulated BMDMs transfected 
with miR-146a mimic compared to controls. (D) No statistically significant 
differences were observed between neurosphere areas using supernatants from 
the negative control or miR-146a mimic. (E) There was no statistically significant 
difference in the number of nucleated neurons within neurospheres cultured in 
supernatant from mouse BMDMs transfected with miR-146a mimic compared to 
controls. (F) There is no statistically significant increase in neuron density in 
neurospheres that were cultured in supernatant from LPS-stimulated mouse 
BMDMs transfected with miR-146a mimic compared to controls. Error bars 
represent the mean +/- standard error of the mean. One-way analysis of variance 
with Dunnett’s post hoc test was used to determine group differences. **p<0.01 
compared to 30nM NC MicroRNA Mimic with LPS stimulation. 
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divided by the number of total nuclei counted, which provided the percentage of 
total cells that were neurons (Figure 17 E). Similar to the total number of neurons 
(Figure 17 C), no differences in neurogenesis were observed. Likewise, to 
normalize the total number of neurons based on neurosphere size, the number of 
"III-Tubulin+ cells was divided by the neurosphere area. Upon normalization for 
neurosphere size, there were no statistically significant differences between the 
experimental groups vs. controls (Figure 17 F). Figure 18 illustrates a 
representative set of mouse neurospheres that were analyzed for neuron 
differentiation.
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Figure 18: Mouse neurospheres cultured in media from LPS-stimulated 
mouse BMDMs transfected with miR-146a mimic had no effect on neuron 
differentiation 
 
(A1) Single mouse neurosphere cultured in media from mouse BMDMs that was 
transfected with 30nM of NC microRNA mimic and stimulated with LPS for 6 
hours. (A2) Identical neurosphere in image A1, with the counted nuclei overlay by 
the program, and the outline of the neurosphere drawn by the researcher. (B1) 
Single mouse neurosphere cultured in media from mouse BMDMs that was 
transfected with 30nM of miR-146a mimic and stimulated with LPS for 6 hours. 
(B2) Identical neurosphere in image B1, with the counted nuclei overlay by the 
program, and the outline of the neurosphere drawn by the researcher.
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3.4.2 Supernatants derived from LPS-stimulated murine BMDMs 
transfected with a miR-146a mimic did not affect oligodendrogenesis 
in vitro  
 
The supernantants applied to murine neurospheres were taken from 
experiments (LPS-stimulated murine BMDMs transfected with a miR-146a mimic) 
where a decrease in TNF was measured (Figure 19 A). The supernatants were 
from newly generated validated supernatants that were not part of Figure 11 A. 
To determine whether supernatants influenced the total number of cells within 
individual neurospheres, the total number of nuclei counted by the program within 
each neurosphere was tallied. No differences in the number of total nuclei were 
observed (Figure 19 B). To determine whether supernatants influenced the total 
number of OPCs (defined by NG2+ cells), the total number of OPCs (from 
counted nuclei) within individual neurospheres was tallied. No statistically 
significant differences were measured across treatment groups (Figure 19 C). 
Similar to the previous experiment, to determine whether the individual 
supernatants influenced overall neurosphere size, the effect of the supernatants 
on individual neurosphere area was measured. No differences were observed 
across all experimental conditions (Figure 19 D). To normalize the total number 
of OPCs per neurosphere, the number of NG2+ cells was divided by the number 
of total nuclei counted, which provided the percentage of total cells that were 
OPCs (Figure 19 E). No differences were observed. To normalize the total 
number of OPCs based on neurosphere size, the number of NG2+ cells was 
divided by the neurosphere area. Upon normalization for neurosphere size, there 
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Figure 19: Oligodendrogenesis analysis from primary mouse neurospheres 
cultured with supernatant from miR-146a-transfected primary mouse 
BMDMs with M1-polarizing conditions   
 
The procedure for the OPC neurosphere assay is described in the Methods and 
Materials section. (A) In all neurosphere differentiation assays, the primary 
mouse BMDM supernatant derived from LPS-stimulated cells transfected with a 
miR-146a mimic had a decrease in TNF compared to negative control (n = 1). (B) 
There was no statistically significant difference in the number of nuclei counted 
within a neurosphere between treatment groups. (C) There was no significant 
difference in the number of differentiated OPCs grown in supernatants derived 
from LPS-stimulated BMDMs transfected with miR-146a mimic compared to 
controls. (D) There was no significant difference in the total area of a 
neurosphere between treatment groups. (E) There was no significant difference 
in the number of nucleated OPCs in neurospheres between different treatment 
groups. (F) There is no significant difference in neuron density in neurospheres 
between treatment groups. Error bars represent the mean +/- standard error of 
the mean. One-way analysis of variance with Dunnett’s post hoc test was used to 
determine group differences.   
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were no statistically significant differences between the experimental groups vs. 
controls (Figure 19 F). Figure 20 illustrates a representative set of mouse 
neurospheres that were analyzed for OPC differentiation.
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Figure 20: Mouse neurospheres cultured in media from LPS-stimulated 
mouse BMDMs transfected with miR-146a mimic had no effect on OPC 
differentiation 
 
(A1) Single mouse neurosphere cultured in media from mouse BMDMs that was 
transfected with 30nM of NC microRNA mimic and stimulated with LPS for 6 
hours. (A2) Identical neurosphere in image A1, with the counted nuclei overlay by 
the program, and the outline of the neurosphere drawn by the researcher. (B1) 
Single mouse neurosphere cultured in media from mouse BMDMs that was 
transfected with 30nM of miR-146a mimic and stimulated with LPS for 6 hours. 
(B2) Identical neurosphere in image B1, with the counted nuclei overlay by the 
program, and the outline of the neurosphere drawn by the researcher.  
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3.5 MiR-146a Increases Phagocytosis of Myelin by Unstimulated 
Primary Mouse Microglia 
 
To assess the potential effect of miR-146a in myelin phagocytosis by 
myeloid cells, a preliminary experiment was conducted using primary mouse 
microglia. Cells were either untreated, or 30nM of miR-146a mimic/negative 
control mimic was transfected into unstimulated primary mouse microglia, and 
subsequently cultured with myelin fragments in vitro. As shown in Figure 21, 
there was a statistically significant increase in the number of myelin-positive 
mouse microglia that were transfected with miR-146a mimic compared to the 
negative control. 
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Figure 21: Myelin phagocytosis increases in miR-146a-transfected primary 
mouse microglia 
 
(A) Image of untreated primary mouse microglia with myelin fragments. (B) Image 
of primary mouse microglia transfected with 30nM of negative control microRNA 
mimic with myelin fragments. (C) Image of primary mouse microglia transfected 
with 30nM of miR-146a mimic with myelin fragments. (D) Percentage of myelin 
positive primary mouse microglia compared to treatments. A statistically 
significant increase in myelin positive primary mouse microglia was seen in 
microglia transfected with miR-146a mimic compared to the negative control. 
Error bars represent the mean +/- standard error of the mean. One-way analysis 
of variance with Dunnett’s post hoc test was used to determine group differences. 
**p<0.01 compared to 30nM NC Mimic with LPS stimulation. Work was 
conducted by Dylan Galloway.  
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Chapter 4 - Discussion 
 
The objective of this thesis was to investigate a potential role for miR-146a 
in altering inflammation, cell differentiation, and tissue regenerative responses in 
the context of MS. Previous work has demonstrated that miR-146a is an 
inflammatory-resolving microRNA that indirectly decreases inflammation through 
a negative feedback mechanism (Boldin et al. 2011; Taganov et al. 2006). A 
failure of the body to increase levels of miR-146a may be suggestive of an 
abnormal or altered pathophysiological response that fails to “halt” inflammation, 
thus indirectly promoting a pro-inflammatory response. It has been recently 
demonstrated that miR-146a levels may decrease in CD68+ myeloid cells 
(macrophages/microglia) within parenchymal MS lesions exhibiting active 
demyelination (Moore et al. 2013) and may suggest that during chronic active 
demyelination, miR-146a expression within myeloid cells may be insufficient to 
resolve chronic inflammation and demyelination. To overcome this potentially 
pathological in situ observation, I hypothesized that elevating miR-146a within 
pro-inflammatory myeloid cells during active demyelinating lesions may lead to 
the polarization of these cells towards an anti-inflammatory and tissue-
regenerative phenotype, thus promoting remyelination and recovery.  
 To test this hypothesis, I performed several in vitro experiments using both 
primary mouse and human myeloid cell populations (macrophages and 
microglia). Specifically, all cells were transfected with a miR-146a mimic, and 
subsequently polarized toward an “M1” pro-inflammatory phenotype, which 
models the activation phenotype often observed within active demyelinating MS 
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lesions (Vogel et al. 2013). To assess whether increasing miR-146a expression 
within these cells resulted in a direct effect on cell phenotype and function, 
experiments were performed to measure production of pro-inflammatory 
cytokines (TNF and IL-6) and gene expression (iNOS and RhoA). Since it has 
been previously demonstrated that soluble factors derived from activated myeloid 
cells can significantly influence the growth of both neurons and oligodendrocyte 
progenitor cells (Moore et al. 2015; Pool et al. 2011), experiments were also 
performed to assess whether altered miR-146a levels within myeloid cells had an 
indirect effect on neurogenesis and oligodendrogenesis. The ability of miR-146a 
to impact phagocytosis of myelin by myeloid cells, a critical requirement to 
promote remyelination within MS lesions, was also performed.  
 In M1-polarized mouse BMDMs, human MDMs, and human fetal/adult 
microglia, a similar result was obtained: increased miR-146a expression 
suggested a decrease in TNF production, but not IL-6 (Figure 11 and Figure 14). 
In contrast, in M1-polarized mouse microglia, the results were opposite: miR-
146a was suggested to decrease IL-6, but not TNF (Figure 11). In both mouse 
and human macrophages, miR-146a may decrease RhoA expression, but may 
not affect iNOS expression (Figure 12 and Figure 15). In human fetal microglia, 
miR-146a may have no effect on RhoA or iNOS expression (Figure 16). 
Supernatants collected from miR-146a-transfected pro-inflammatory mouse 
macrophages did not significantly affect neurogenesis (Figure 17) or 
oligodendrogenesis (Figure 19) in vitro. Finally, increased miR-146a levels 
resulted in an increase in the phagocytosis of myelin in resting mouse microglia 
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(Figure 21). The following sections will discuss these findings in the context of 
the current literature and its significance to MS. 
 The first inflammatory cytokine examined was tumour necrosis factor 
(TNF). M1 cells are often characterized by elevated TNF expression (Mantovani 
et al. 2004), which is a highly relevant cytokine in MS pathology. In rodents, TNF 
accelerates experimental autoimmune encephalomyelitis (EAE) onset and 
promoted inflammatory cell recruitment to the CNS (Kruglov et al. 2011). TNF 
also promotes demyelination, myelin sheath dilation, and death of 
oligodendrocytes and neurons (Selmaj and Raine 1988a; Selmaj and Raine 
1988b). In addition, TNF suppresses phagocytosis of toxic myelin fragments 
(Brück et al. 1992), blocks neuronal development from NSCs/neurogenesis (Liu 
et al. 2005; Monje et al. 2003), and damages primary human oligodendrocytes in 
vitro (D'Souza et al. 1996). The detection of TNF in human CSF was variable in 
MS studies. Some studies indicated that TNF levels in the CSF were rarely 
detected, regardless of pathological state (Franciotta et al. 1989; Gallo et al. 
1989; Malmestrom et al. 2006; Peter et al. 1991; Vladic et al. 2002). On the other 
hand, elevated TNF levels in the CSF have been detected in MS patient samples 
compared to controls (Maimone et al. 1991; Sharief and Hentges 1991; Tsukada 
et al. 1991) and was more frequently detected in active MS compared to other 
neurological diseases (Hauser et al. 1990). In serum, TNF was rarely detected in 
MS serum or in controls (Franciotta et al. 1989; Gallo et al. 1989; Maimone et al. 
1991; Malmestrom et al. 2006; Peter et al. 1991; Vladic et al. 2002). In the 
context of both CSF and serum TNF levels, since the majority of these studies 
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were performed 25+ years ago, the failure to detect TNF might have been due to 
technical limitations, including a possible lack of robust ELISAs. In other studies, 
if TNF was readily detectable in the serum of MS patients, there was no 
significant increase compared to controls (Tsukada et al. 1991). Despite these 
mixed results, TNF expression in both MS lesions and PBMCs has a more 
convincing role in MS pathophysiology. For example, elevated TNF mRNA has 
been reported in several studies, including: 1) PBMCs from patients with active 
RRMS compared to stable RRMS and non-inflammatory neurologic disease 
controls (Rieckmann et al. 1994); 2) PBMCs from clinically active RRMS patients 
and RRMS patients with active lesions compared to stable RRMS patients and 
healthy controls (Rieckmann et al. 1995); 3) PBMCs from MS patients compared 
to healthy controls (Navikas et al. 1996a); 4) PBMCs preceding clinical 
symptoms of a relapse in RRMS patients (Rieckmann et al. 1995); and 5) whole 
blood from MS patients experiencing a relapse compared to healthy controls 
(Kahl et al. 2002). In active MS lesions, TNF protein/mRNA increases have also 
been observed (Cannella and Raine 1995; Selmaj et al. 1991; Woodroofe and 
Cuzner 1993), including within macrophages/microglia (Cannella and Raine 
1995; Selmaj et al. 1991; Woodroofe and Cuzner 1993). Taken together, I 
suggest that reducing TNF during active demyelination in MS may encourage 
oligodendrocyte/neuron viability, remyelination, and recovery.  
 The ability of miR-146a to influence TNF expression has been previously 
examined in rodent studies. A majority of studies using the murine macrophage 
cell line, RAW264.7, have found that miR-146a led to a decrease in TNF protein 
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or mRNA following infection with mycobacteria (Li et al. 2013b), 
hypoxia/reoxygenation (Jiang et al. 2014), or stimulation with LPS and IFN! 
(Huang et al. 2016). In one study, following LPS activation, increased miR-146a 
levels did not decrease TNF protein or mRNA compared to controls (He et al. 
2014). In an additional murine macrophage cell line (J774 cells), delivery of a 
miR-146a mimic also decreased TNF protein (Gao et al. 2015b). A reduction of 
TNF protein and/or mRNA due to a miR-146a mimic transfection was also 
observed in both pro-inflammatory primary murine peritoneal macrophages (Gao 
et al. 2015a) and murine BMDMs (He et al. 2016). In an in vitro model of Lyme 
arthritis, BMDMs derived from miR-146a-knockout mice and subsequently 
infected with the bacteria Borrelia burgdorferi in vitro had increased TNF 
production compared to controls (Lochhead et al. 2014). In summary, a majority 
of the studies suggest that increasing miR-146a levels under pro-inflammatory 
states leads to decreased TNF production in mouse macrophages, a result that I 
also observed in primary mouse BMDMs (Figure 11). However, this did not 
translate to primary mouse microglia (Figure 11). While this thesis did not 
investigate the possible mechanisms responsible for this discrepancy between 
myeloid cell subsets in mice, differences in inflammatory pathways between the 
cell types may exist. A possible explanation could include that signalling 
pathways modulating pro-inflammatory cytokine release, via miR-146a, is more 
tightly regulated in brain-derived microglia compared to macrophages. 
 In addition to animal studies, the effect of miR-146a on TNF production 
has also been investigated in human cells. Using the transformed THP-1 
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monocyte/monocyte-derived macrophage (MDM) human cell line, miR-146a 
decreased TNF mRNA/protein under pro-inflammatory conditions (Li et al. 
2016a; Liu et al. 2014; Nahid et al. 2009; Nahid et al. 2013; Pauley et al. 2011). 
These results are consistent with the suggested reduction in TNF production in 
M1-polarized THP-1 MDMs transfected with a miR-146a mimic (Figure 13). In an 
in vitro model of viral-induced encephalitis, miR-146a also decreased TNF 
protein produced by cultured human CHME3 microglia cell lines infected with a 
strain of the Japanese encephalitis virus (JEV) (Sharma et al. 2015). In this 
thesis, I am the first to report that these results have been replicated in healthy 
primary human pro-inflammatory MDMs transfected with a miR-146a mimic 
(Figure 14). In addition, although speculative at this time, miR-146a may 
decrease TNF production from M1 human adult microglia (in agreement with the 
literature above), although miR-146a may have no effect on TNF production from 
M1 human fetal microglia. This suggests that the developmental age of human 
microglia may alter the ability of miR-146a to affect TNF production in this cell 
type. Using primary healthy human cells, these results are a more accurate 
representation of the role of miR-146a in humans compared to transformed cell 
lines or cells derived from diseased individuals. Based on these findings from 
primary human and mouse cells, I conclude that further testing of 
oligodendrocyte/neuron viability, remyelination, and recovery in MS, in the 
context of miR-146a, is warranted. 
 In addition to TNF, I was also interested in investigating whether 
increasing miR-146a in pro-inflammatory myeloid cells had an effect on IL-6. First 
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discovered as a B cell differentiation factor (Hirano et al. 1986), IL-6 has several 
biological roles related to the immune, cardiovascular, nervous, and endocrine 
systems (Kishimoto et al. 1995). Most commonly, IL-6 is considered to be a pro-
inflammatory molecule with elevated expression in M1-polarized cells (Mantovani 
et al. 2004); however, several studies have also highlighted the pleiotropic nature 
of IL-6, which has been demonstrated to have both pro- and anti-inflammatory 
properties (Scheller et al. 2011). 
Similar to TNF, IL-6 is relevant in MS pathophysiology. Evidence of 
increased IL-6 expression is observed in both MS and its animal models. In 
rodent EAE, IL-6 cytokine/mRNA expression is increased in the CNS (Gijbels et 
al. 1990; Kennedy et al. 1992; Okuda et al. 1995) and correlates with disease 
severity; IL-6 levels also decrease during remyelination (Kennedy et al. 1992; 
Okuda et al. 1995). The detection of IL-6 in human CSF was variable in MS 
studies. Some studies indicate that IL-6 levels in the CSF were rarely detected, 
regardless of pathological state (Hauser et al. 1990; Vladic et al. 2002; 
Wullschleger et al. 2013). In studies that did detect IL-6, the results were highly 
variable (Frei et al. 1991; Maimone et al. 1991; Navikas et al. 1996b; Padberg et 
al. 1999; Stelmasiak et al. 2001; Stelmasiak et al. 2000). In serum, some studies 
suggested that IL-6 was rarely detected in MS and control samples (Malmestrom 
et al. 2006; Vladic et al. 2002). In other studies, if serum IL-6 was readily 
detectable, a similar variability was observed (Frei et al. 1991; Maimone et al. 
1991; Navikas et al. 1996b; Padberg et al. 1999; Stelmasiak et al. 2001). In 
whole PBMCs, there is some evidence to suggest that IL-6 is altered in MS. One 
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study by Rieckmann et al. found evidence to suggest that IL-6 mRNA was 
significantly increased in patients with active RRMS compared to stable disease 
(Rieckmann et al. 1994), however, no correlation between relapses and activity 
were noted in a follow-up study (Rieckmann et al. 1995). In a separate study, it 
was suggested that blood monocytes derived from MS patients may be “primed”, 
as cultured unstimulated blood monocytes from MS patients spontaneously 
produced significantly higher IL-6 concentrations compared to controls (Maimone 
et al. 1993).  
In MS lesions, Woodroofe et al. found that IL-6 mRNA expression was 
present in inflammatory perivascular lesions, regardless of whether 
demyelination was minimal or extensive (Woodroofe and Cuzner 1993); 
however, IL-6 mRNA levels were higher in inflammatory lesions with extensive 
demyelination (Woodroofe and Cuzner 1993). In a study by Maimone et al., a 
similar observation was noted; IL-6 protein expression was elevated in both 
acute and chronic active plaques, but reduced in chronically silent plaques 
(Maimone et al. 1997). Interestingly, in a study comparing lesion activity, the 
highest total number of IL-6 protein-expressing cells included astrocytes and 
macrophages/microglia within inactive demyelinated lesions; a positive 
correlation was observed between the numbers of IL-6 protein-expressing cells 
and the numbers of oligodendrocytes (Schönrock et al. 2000). As the authors 
noted, this study suggested that the presence of IL-6-expressing cells may 
encourage oligodendrocyte survival and viability.  
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Similar to other inflammatory diseases, the role of IL-6 in the context of 
MS pathology is complex as it appears to have both pro- and anti-inflammatory 
properties. IL-6 has an anti-inflammatory effect on monocytes/macrophages by 
increasing the production of anti-inflammatory cytokines IL-4 and IL-10 (Duluc et 
al. 2007; Frisdal et al. 2011), which promote an anti-inflammatory phenotype in 
microglia and macrophages. Furthermore, IL-6 increases the expression of 
several genes associated with the M2-polarized phenotype of 
monocytes/macrophages (Duluc et al. 2007; Frisdal et al. 2011; Roca et al. 
2009), which has been suggested to be beneficial during MS recovery (Miron et 
al. 2013; Peferoen et al. 2015; Vogel et al. 2013). IL-6 also has an anti-
inflammatory effect on OPCs/oligodendrocytes. There is evidence that IL-6 
bound with its soluble receptor encourages rodent OPC differentiation into 
mature oligodendrocytes and survival in vitro (Valerio et al. 2002), and either IL-6 
alone or IL-6 bound with its soluble receptor rescued oligodendrocytes from 
excitotoxic injury in vitro while preserving and encouraging myelin production 
(Pizzi et al. 2004). Although IL-6 can negatively affect rodent neurogenesis in 
vitro (Monje et al. 2003), there is evidence to suggest that IL-6 can have an anti-
inflammatory effect on neurons by promoting neuronal and axonal regeneration 
(Ali et al. 2000; Cafferty et al. 2004; Cao et al. 2006; Fisher et al. 2001; Hirota et 
al. 1996; Pizzi et al. 2004; Zhong et al. 1999). In the context of animal models of 
MS, manipulating IL-6 expression using relevant animal models has not yielded 
conclusive results. Using the Theiler’s Murine Encephalomyelitis Virus (TMEV) 
model of demyelination, systemic administration of IL-6 before or after the viral 
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infection reduced demyelination (Rodriguez et al. 1994); however, rodents orally 
gavaged with tocilizumab (Actemra®) (antihuman IL-6 receptor antibody that 
blocks IL-6 activity) during rodent EAE suppressed disease activity (Brod and 
Bauer 2014), suggesting that blocking IL-6 signalling may be beneficial in treating 
MS. Taken together, as IL-6 signalling appears to be important in MS biology, I 
investigated whether increasing miR-146a expression in macrophages and 
microglia had an effect on IL-6 production. 
In murine studies, the effect of miR-146a on IL-6 production has been 
previously investigated. Similar to the TNF result, using miR-146a knockout mice, 
untreated BMDMs had a basally higher IL-6 mRNA expression compared to wild-
type (Zhao et al. 2013). In addition, transfection of a miR-146a mimic also 
decreased IL-6 protein/mRNA in the RAW264.7 mouse macrophage cell line 
when exposed to either hypoxia/reoxygenation (Jiang et al. 2014), LPS (He et al. 
2014), or a strain of Mycobacterium bovis (Li et al. 2013b). In addition, BMDMs 
derived from miR-146a knockout mice secreted higher concentrations of IL-6 in 
vitro compared to controls when subsequently infected with the Borrelia 
burgdorferi bacterium (Lochhead et al. 2014). In vitro, pre-miR-146a reduced IL-6 
production in the murine BV-2 microglia cell line (Gushue 2014) upon stimulation 
with toll-like receptor 2 (TLR2) agonist heat-killed Listeria monocytogenes 
(HKLM) bacteria. A dual-luciferase assay has also suggested that the 3’-
untranslated region of IL-6 mRNA is a direct target of pre-miR-146a (Zhou et al. 
2015). Based on these findings, I investigated whether miR-146a might also 
decrease IL-6 in primary mouse macrophages and microglia. MiR-146a 
 95 
significantly decreased IL-6 cytokine production in M1-polarized mouse microglia, 
however, it had no significant effect on M1 mouse macrophages (Figure 11). In 
addition, the differences between miR-146a regulating IL-6 between mouse 
BMDMs and microglia may indicate that the miR-146a/IL-6 pathway is more 
tightly regulated in mouse macrophages compared to mouse microglia.                                                                                                   
The effect of miR-146a on IL-6 expression has been previously examined 
in human studies. Using THP-1 monocytes/MDMs, miR-146a reduced IL-6 
mRNA under pro-inflammatory conditions (Li et al. 2016a; Nahid et al. 2009; 
Pauley et al. 2011). These results are consistent with the suggested reduction of 
IL-6 production by M1-polarized pro-inflammatory THP-1 MDMs in this thesis 
(Figure 13). MiR-146a also decreased IL-6 in a human CHME3 microglia cell line 
infected with a strain of the Japanese encephalitis virus (Sharma et al. 2015); 
however, in contrast to the cell line, the current results suggest that miR-146a 
does not alter IL-6 production from M1-polarized primary human MDMs, and may 
not alter IL-6 production from M1-polarized primary human fetal/adult microglia 
(Figure 14). This discrepancy between primary cells and cell lines may be 
explained by the lack of genetic and phenotypic variability between cells within a 
cell line. In contrast, primary human cells often possess greater heterogeneity, 
thus often leading to more variability, particularly when assessing immune 
responses.  
Following the assessment of miR-146a to influence inflammatory cytokine 
production in pro-inflammatory mouse and human macrophages and microglia, I 
sought to elucidate a possible mechanism by measuring the protein expression 
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of two genes that have been previously validated as a target of miR-146a, 
inducible nitric oxide synthase (iNOS) and RhoA (Gushue 2014; Liu et al. 2016; 
Wu et al. 2015). As discussed below, both iNOS and RhoA are relevant proteins 
in MS pathology and their inhibition may encourage remyelination.  
iNOS (also known as NOS2) is one of three known subtypes of nitric 
oxidase synthase (NOS); the others being neuronal (nNOS or NOS1) and 
endothelial (eNOS and NOS3) (Ghasemi and Fatemi 2014). Typically, when 
iNOS is induced, usually by infection, inflammatory stimuli, and/or bacterial 
products, NO is produced, which can destroy viral and microbial pathogens, and 
in some cases, can potentially be cytotoxic (Aktan 2004). In murine EAE, iNOS 
mRNA production in the CNS is primarily expressed in infiltrating macrophages 
and positively correlates with EAE severity (Okuda et al. 1995). In MS lesions, 
iNOS mRNA is also increased in myeloid-lineage cells (Bagasra et al. 1995; Bö 
et al. 1994a; Hooper et al. 1997). In rodents, NO has been reported to have 
many pathological functions, including: 1) disrupting/increasing BBB permeability 
(Mayhan 2000; Shukla et al. 1995; Shukla et al. 1996); 2) promoting damage and 
death to oligodendrocytes (Merrill et al. 1993; Mitrovic et al. 1994; Mitrovic et al. 
1995; Mitrovic et al. 1996); and 3) preventing neuronal electrical conduction and 
promoting neuronal damage (Bonfoco et al. 1995; Garthwaite et al. 2002; 
Redford et al. 1997; Shrager et al. 1998). In humans, NO decreases MBP gene 
expression in primary myelinating oligodendrocytes in vitro (Jana and Pahan 
2013). iNOS and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 
by rodent microglia can lead to the production of NO and superoxide to form 
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peroxynitrite, which kills rodent oligodendrocytes (Li et al. 2005). Given the 
pathophysiological relevance of iNOS in MS pathology, inhibiting iNOS may be 
beneficial in preventing demyelination and neurodegeneration. In rodents, 
inhibition of iNOS through drug administration using inhibitors of iNOS 
(tricyclodecan-9-yl-xanthogenate (D609) or aminoguanidine) or an antisense 
oligodeoxynucleotide to iNOS mRNA prevented EAE induction and/or reduced 
EAE symptoms (Ding et al. 1998; Hooper et al. 1997; Pozza et al. 2000).  
The direct effect of miR-146a on iNOS expression has been previously 
investigated in both murine macrophage and microglia cell lines, and in vivo. In 
vitro, miR-146a decreased iNOS mRNA (Li et al. 2016b) and protein (Huang et 
al. 2016) in pro-inflammatory RAW264.7 mouse macrophages, and decreased 
iNOS mRNA in pro-inflammatory rat macrophages from the Kupffer cell line (He 
et al. 2016). Pre-miR-146a also reduced iNOS protein in mouse BV-2 microglia 
following stimulation with the TLR2 agonist HKLM bacteria (Gushue 2014). Using 
the cuprizone-induced model of demyelination, mice continuously infused with 
Cy3-labeled miR-146a mimic into the corpus callosum had reduced iNOS protein 
(Zhang et al. 2017). Collectively, these studies provide strong evidence to 
suggest that miR-146a is likely to decrease iNOS in pro-inflammatory 
macrophages and microglia; however, in my current results, transfection of a 
miR-146a mimic in primary mouse BMDMs was suggested to have no effect on 
iNOS production (Figure 12). This discrepancy may be due to the kinetics of 
iNOS expression. The current experiment measured iNOS levels after 6hrs of 
LPS stimulation; however, previous studies have measured iNOS protein at later 
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time points, such as 12hrs using LPS and IFNγ (Huang et al. 2016) or 24hrs 
using TLR2 agonist HKLM (Gushue 2014). The 6hr time-point was originally 
selected as the most-optimal time-point to assay pro-inflammatory cytokine 
production,which are rapidly released upon stimulation in general. It is possible 
that had the experiment continued beyond 6hrs, the LPS-only and negative 
controls would continue producing iNOS, while cells transfected with a miR-146a 
mimic would produce less iNOS over time. Future experiments should examine 
iNOS expression in miR-146a-transfected cells at later time-points. 
 The effect of miR-146a on iNOS production has been previously 
investigated in pro-inflammatory M1 human THP-1 MDMs; however, similar 
experiments have not been performed in primary healthy human MDMs and 
microglia. MiR-146a decreased iNOS protein in M1-polarized THP-1 MDMs (Li et 
al. 2016a). For the first time, in primary cells from healthy volunteers, there is 
evidence to suggest that miR-146a may not decrease iNOS protein in M1-
polarized primary human MDMs and fetal microglia 6hrs after LPS stimulation 
(Figure 15 and Figure 16). Similar to mouse studies, the inability of miR-146a to 
reduce iNOS may be due to the 6hr time-point. Following stimulation, a longer 
time-point (12-48hrs) may be required. For example, Li et al. investigated iNOS 
expression 24hrs after pro-inflammatory stimulated miR-146a-transfected THP-1 
MDMs (Li et al. 2016a). Furthermore, in a kinetic study of iNOS using mixed 
human glial cultures containing both astrocytes and microglia, Ding et al. found 
that iNOS protein started to peak beginning at the 24-48hr time-point following 
stimulation with interleukin-1 " (IL-1") and IFN! (Ding et al. 1997).  
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RhoA was also examined in pro-inflammatory mouse and human myeloid 
cells as a possible downstream target of miR-146a. Part of the Ras superfamily 
of Rho GTPases (Rojas et al. 2012), most Rho (Ras-homologous (Ridley 2001)) 
GTPases function as switches in biological processes by converting between 
active (GTP-bound) and inactive (GDP-bound) conformation states, thus 
regulating several signalling transduction pathways (Hall 2012). In the Rho 
subfamily, there are three isoforms: RhoA, RhoB, and RhoC (Bustelo et al. 2007; 
Wheeler and Ridley 2004). Rho A/B/C are well-known for their roles in regulating 
cell shape and movement by altering actomyosin contractility, actin 
polymerization, microtubules, and cell adhesion (Ridley et al. 2003; Wheeler and 
Ridley 2004). In the literature, RhoA is the most highly studied. As a regulator of 
several signal transduction pathways, RhoA regulates the Rho/Rho kinase 
pathway (Amano et al. 2010). Inhibition of RhoA translation is therefore likely to 
prevent the activation of Rho-kinase downstream and has been previously 
investigated in MS. In CNS lesions of EAE mice, RhoA expression is positively 
correlated with EAE severity (Zhang et al. 2008). In MS, a high number of RhoA+ 
cells were also detected in active MS lesions; RhoA+ cells were reduced in 
chronic lesions and absent in control brains (Zhang et al. 2008). In both EAE and 
MS lesions, the majority of RhoA+ cells were macrophages/microglia (Zhang et 
al. 2008). As mentioned previously, remyelination in the CNS occurs most 
efficiently following the clearance of cellular debris and myelin fragments via 
phagocytosis. Phagocytosis of myelin by primary mouse microglia has been 
previously reported to be increased following inhibition of RhoA (Gitik et al. 
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2010). In both unstimulated J774 murine macrophages and primary mouse 
macrophages, overexpression of RhoA inhibited phagocytosis of apoptotic 
thymocytes (Nakaya et al. 2006; Tosello-Trampont et al. 2003). Inhibiting RhoA 
may also decrease the migration of monocytes/macrophages across the BBB by 
inhibiting diapedesis across transendothelial membranes/endothelial monolayers 
(Honing et al. 2004; Worthylake et al. 2001). In addition to implicating RhoA, 
targeting the Rho/Rho-associated protein kinase pathway has also been 
suggested to improve MS and EAE pathology. In EAE, selective inhibitors of 
Rho-associated protein kinase (ROCK) improved clinical severity, decreased 
demyelination, reduced the number of inflammatory foci in the spinal cord, and 
shifted mouse macrophages/microglia from an M1 to an M2 phenotype (Hou et 
al. 2012; Liu et al. 2013). In addition to directly targeting RhoA, activation of the 
Rho/ROCK pathway inhibits axonal regeneration, neurite growth, and 
synaptogenesis (Chen et al. 2015; Liu et al. 2015). Collectively, inhibiting RhoA 
and/or the Rho/ROCK pathway in inflammatory monocytes and macrophages 
(via expression of miR-146a) may limit their movement across the BBB during 
active demyelination, increase the clearance of myelin and cellular debris, and 
promote remyelination and recovery in MS.  
 To date, the ability of miR-146a to influence RhoA expression in primary 
mouse and human macrophages and microglia has not been examined. In both 
primary mouse and human MDMs, there is evidence to suggest that miR-146a 
may reduce RhoA expression (Figure 12 and Figure 15); there is also evidence 
to suggest that miR-146a has no effect on RhoA in primary human fetal microglia 
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(Figure 16). A possible reason for the observed difference between blood-derived 
macrophages and microglia may indicate that the ability of miR-146a to influence 
RhoA expression is more tightly regulated in human microglia compared to 
mouse BMDMs and/or human MDMs. Although speculative, one could argue that 
the reason RhoA is more tightly regulated in microglia compared to MDMs is due 
to the innate differences in cellular function. For example, microglia are “tissue-
resident macrophages” of the CNS, where they specifically develop and reside 
only in the CNS throughout their life cycle. As a permanent resident of the CNS, 
it can be argued that their function is closely in tandem with the health of the 
CNS. If their functionality could be quickly and easily altered, such as quickly 
increasing or decreasing RhoA expression without being tightly regulated, it 
could quickly alter the homeostatic balance of the CNS. On the other hand, 
MDMs are short-lived, do not reside within the CNS, and originate as circulating 
blood monocytes in the blood. MDMs can be considered more adaptable/plastic 
than microglia in the sense that they must be able to enter a wide range of 
tissues upon immune challenge, a mechanism that can be controlled acutely by 
microRNAs.  
 Based on my results and the current literature, the following signalling 
cascade between miR-146a, RhoA, and TNF was proposed. Previous studies 
have noted that LPS stimulates the toll-like receptor 4 (TLR4) in macrophages (Li 
and Cherayil 2003; Wu et al. 2009). When TLR4 is activated, TNF protein can be 
produced through the myeloid differentiation primary response 88 (MyD88) 
dependent pathway (Li et al. 2013a). This pathway requires IRAK1 and TRAF6, 
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leading to the activation of NF-kB and the production of inflammatory cytokines, 
including TNF (Li et al. 2013a). Previously, RhoA has also been found to 
increase in human monocytes after LPS stimulation (Chen et al. 2002), and there 
is evidence to suggest that it is also involved in the activation of NF-kB in human 
monocytes/macrophages (Chen et al. 2002; Huang et al. 2009). MiR-146a has 
been previously known to be a potential target of IRAK1 and TRAF6 (Taganov et 
al. 2006) and RhoA in luciferase assays (Liu et al. 2016; Wu et al. 2015). My 
results suggest that expressing miR-146a may lead to a reduction of both RhoA 
and TNF in LPS-stimulated primary mouse BMDMs and human MDMs. 
Therefore, it is possible that endogenous increases in miR-146a levels within 
these cells causes an inhibition of RhoA, IRAK1, and TRAF6, which 
consequently curbs the production of TNF protein. This proposed scheme is 
illustrated in Figure 22. 
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Figure 22: Proposed scheme of signalling pathways between miR-146a, 
TNF, and RhoA in either primary mouse BMDMs or human MDMs after 6 
hours of LPS stimulation 
Based on the current literature (Chen et al. 2002; Huang et al. 2009; Li et al. 
2013a; Liu et al. 2016; Taganov et al. 2006; Wu et al. 2015), and the results from 
miR-146a-transfected primary mouse and human cells with LPS stimulation, the 
following scheme was proposed. When LPS triggers TLR4, the MyD88 
dependent pathway is activated. RhoA may increase due to LPS stimulation, and 
is required, along with IRAK1 and TRAF6, to activate NF-#B, which leads to the 
production of TNF. However, an increase in endogenous miR-146a may inhibit 
the production of RhoA/IRAK1/TRAF6, and therefore reducing the amount of 
TNF produced and released into the extracellular space. 
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 The effect of miR-146a on myelin phagocytosis in primary mouse and 
human myeloid cells has not been previously investigated; however, it has been 
examined in cell lines. MiR-146a-transfected RAW264.7 mouse macrophages, 
when infected with the Mycobacterium bovis bacillus Calmette-Guérin (M. bovis 
BCG), had no effect on the phagocytosis of fluorescently labelled M. bovis BCG 
(Li et al. 2016b). However, THP-1 monocytes transfected with pre-miR-146a 
increased their phagocytosis of Escherichia coli bacteria (Pauley et al. 2011). In 
preliminary experiments, transfection of a miR-146a mimic increased myelin 
phagocytosis in unstimulated primary mouse microglia (Figure 21), suggesting 
that miR-146a exerts an anti-inflammatory role and has the potential to promote 
the clearance of myelin debris.  
As previously mentioned, the recruitment of neural stem/progenitor cells and 
OPCs occurs during remyelination and is required to promote neurogenesis, 
oligodendrogenesis, and repair (Chang et al. 2008; Di Bello et al. 1999; Nait-
Oumesmar et al. 1999; Nait-Oumesmar et al. 2007; Picard-Riera et al. 2002; 
Xing et al. 2014). In vitro, neuronal differentiation was increased following 
transfection of a miR-146a mimic in mouse neural stem cells (Mei et al. 2011). 
Increased MBP+ OPCs has also been observed in both primary rat embryonic 
OPCs and in the N20.1 mouse OPC cell line transfected with a miR-146a mimic 
(Santra et al. 2014). In vivo, in a mouse model of cuprizone-induced 
demyelination, Cy3–labelled miR-146a continuously infused into the corpus 
collosum targeted OPCs, increased differentiation into myelinating 
oligodendrocytes, and promoted remyelination (Zhang et al. 2017). Collectively, 
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these studies suggest that miR-146a may directly promote neurogenesis and/or 
oligodendrogenesis. Since it is known that soluble factors released from 
activated myeloid cells (both rodent and human) can directly influence 
neurogenesis and oligodendrogenesis, I examined whether the differences I 
observed in myeloid cells following transfection with a miR-146a mimic had an 
indirect effect on neuronal and/or oligodendrocyte cell fate. This thesis examined 
the indirect effect of miR-146a on neurogenesis/oligodendrogenesis via myeloid 
cells, specifically from mouse BMDMs. Using supernatants collected from LPS-
stimulated miR-146a-transfected mouse macrophages, no significant effect on 
either neurogenesis or oligodendrogenesis was observed (Figure 17 and Figure 
19). In vitro experiments, by design, serve as a model of biological processes 
occurring in vivo and possess inherent limitations. Although supernatants derived 
from miR-146a-transfected mouse macrophages did not significantly affect 
neurogenesis and/or oligodendrogenesis directly within the confines of this 
model, it is possible that under pro-inflammatory conditions, increased miR-146a 
expression within myeloid cells in vivo may directly influence neurogenesis and 
oligodendrogenesis (as observed in previous studies). For example, miR-146a is 
thought to promote phagocytosis of myelin fragments in myeloid cells. As 
previously mentioned, the clearance of toxic myelin fragments is required for 
neural stem cell/OPC survival. As found in this study using mouse microglia 
(Figure 21), there is evidence that miR-146a transfected cells may increase 
phagocytosis of myelin fragments. Furthermore, as least in evidence in mouse 
BMDMs (Figure 12) and human MDMs (Figure 15), limiting RhoA expression in 
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pro-inflammatory macrophages by miR-146a could also increase phagocytosis of 
myelin (Gitik et al. 2010) and apoptotic cells (Nakaya et al. 2006; Tosello-
Trampont et al. 2003), which is associated with inhibiting RhoA. Another way 
miR-146a-transfected cells could influence OPC and neural stem cell fate is 
through the reduction of pro-inflammatory cytokine signalling towards other cells. 
As seen in both primary mouse and human macrophages and microglia, a 
reduction in TNF could help in curbing pro-inflammatory signalling toward other 
cells that provide growth factors and support to neural stem cells during active 
demyelination, especially astrocytes. This effect of curbing pro-inflammatory 
responses from myeloid cells to other cells could also be improved by the 
maintaining of a strong IL-6 response, which has been shown to induce anti-
inflammatory IL-4 (Frisdal et al. 2011) and IL-10 (Duluc et al. 2007; Frisdal et al. 
2011), promote the M2 anti-inflammatory phenotype (Duluc et al. 2007; Frisdal et 
al. 2011; Roca et al. 2009), and increase phagocytosis of apoptotic cells (Frisdal 
et al. 2011). Although ROS production was not measured in these cells, and 
collected only 6 hours post-stimulation (a very acute time-point), a potential lack 
of ROS production may help to explain why no differences were observed in 
either neurogenesis or oligodendrogenesis.  
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Chapter 5 - Future Directions 
There are limitations to the current study. All experiments were performed 
in vitro, which may not accurately reflect activities in vivo. Furthermore, due to 
time and availability of resources (e.g. primary human brain tissue), experiments 
with n<3 will need to be repeated to determine if the suggested effects by miR-
146a are indeed biologically and statistically significant. 
In continuing to explore how miR-146a is relevant to MS pathophysiology, 
remyelination, and CNS repair, there are several potential steps forward. These 
steps can be broadly classified under two categories: 1) modifications to the 
current experiments, and 2) developing experiments outside the scope of this 
thesis. Each category will be briefly discussed.  
The first set of future directions fall under modifications to the described 
experiments. The first modification would be performing additional TNF and IL-6 
ELISAs on human fetal and adult microglia experiments to determine whether 
transfection of a miR-146a mimic has a statistically significant effect on TNF and 
IL-6 production. Unfortunately, these cells are difficult to obtain, and therefore 
only a few samples were available for use. The second modification would be to 
continue to measure TNF, IL-6, iNOS, and RhoA production in M1-polarized 
myeloid cells transfected with a miR-146a mimic at various time points (at 6hrs 
and beyond), with an n = 3 for a single time point. Due to the unexpected lack of 
effect of miR-146a on cytokine and gene production in some primary cells 
compared to previous studies, it may suggest that the interactions between miR-
146a and possible target genes is kinetically different. Examining cytokine and/or 
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gene production at other time points (e.g. 24-96hrs), may provide additional 
insight. The final modification to the current experiments would be to assess the 
ability of miR-146a to influence myelin phagocytosis in mouse and human 
microglia initially polarized towards either a pro-inflammatory (M1) or anti-
inflammatory (M2) phenotype. It is possible that miR-146a may have a different 
effect on cells originally polarized towards an activated phenotype (compared to 
naïve cells), which is typically seen in MS lesions and during active 
demyelination.   
 Besides modifying existing experiments, there are also several additional 
experiments that could be performed to expand the scope of this investigation. 
First, laser-capture microdissection could be used to examine any differences in 
miR-146a levels between different types of lesions in untreated RRMS patients, 
or in other MS types, such as untreated SPMS or PPMS patients. Such 
differences in expression of this anti-inflammatory microRNA is already evident 
from PBMCs of untreated RRMS patients (higher), compared to untreated SPMS 
and PPMS patients (lower than RRMS and similar to controls) (Fenoglio et al. 
2011). By examining differences in this microRNA between lesions of different 
MS types, it may reveal that miR-146a has a role to play in: 1) the stages of 
demyelinating and remyelinating lesions; 2) the transition from RRMS to SPMS; 
and 3) remission incidence and frequency. Second, the effect of a miR-146a 
mimic could be examined in the lysolecithin model of demyelination. Although 
effect of miR-146a has been previously examined in a cuprizone demyelination 
model with several potentially therapeutic benefits (Zhang et al. 2017), cuprizone 
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is orally administered in chow, and demyelinates several white matter areas in 
the brain (Denic et al. 2011). One advantage of the lysolecithin model over the 
cuprizone model is that one can measure and control demyelination and 
remyelination within defined anatomic regions of the CNS (Denic et al. 2011; 
Lassmann and Bradl 2017). It also has a pre-defined, predictable timeline of 
pathology when demyelination and remyelination peak (Keough et al. 2015). In 
addition to the lysolecithin model, it would also be interesting to examine the 
effect of miR-146a administered to EAE mice, however, route of administration 
and the dosing of microRNA mimics remains a significant barrier for in vivo 
applications. Third, it would be interesting to assess the effect of miR-146a on 
ROS production, both in primary mouse and human blood-derived macrophages 
and microglia. Although examining iNOS expression is important, ROS are the 
actual compounds that can kill cells critical for remyelination. Examining the 
amount of ROS produced by miR-146a-transfected primary myeloid cells would 
be important to determine if miR-146a could limit excessive ROS production and 
encourage the survival of these cells. Fourth, assessing myelin and apoptotic 
phagocytosis by miR-146a-transfected primary M1 mouse/human microglia and 
blood-derived macrophages would be interesting to determine if miR-146a had 
an effect on clearing debris, which is required for remyelination. Fifth, it would be 
interesting to assess the effect of miR-146a on the shift from M1 to M2 
phenotypes in mouse/human microglia/blood-derived macrophages using 
traditional M1 markers (such as CD80 and CCR7) and M2 markers (such as 
CD23, CD163, CD206, and CD209) by flow cytometry (Durafourt et al. 2012). 
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Finally, another experiment could be assessing miR-146a-transfected M1-
polarized mouse microglia and human MDMs/microglia on 
neurogenesis/oligodendrogenesis in vitro, and possibly assessing the types of 
neurons that can be generated. Since this thesis only examined the effect of 
miR-146a-transfected murine BMDMs on mouse NSCs, additional experiments 
could be performed to assess how miR-146a may indirectly improve 
neurogenesis/oligodendrogenesis using mouse microglia. Furthermore, the 
ability of miR-146a-transfected primary human microglia and/or MDMs on human 
NSCs could also be assessed.  
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Chapter 6 - Conclusion 
This thesis investigated the therapeutic potential of promoting miR-146a 
expression within macrophages and microglia in the context of MS 
pathophysiology, remyelination, and CNS repair. In pro-inflammatory myeloid 
cells, increasing miR-146a expression resulted in functions that could be 
interpreted as being anti-inflammatory and beneficial for promoting remyelination. 
Overexpression of miR-146a suggested a decrease in pro-inflammatory TNF but 
little or no effect on IL-6. Overexpression of miR-146a also suggested that it had 
no effect on iNOS production, but may decrease RhoA expression in both mouse 
and human blood-derived macrophages after 6 hours of LPS stimulation. 
Unstimulated primary mouse microglia that were transfected with miR-146a 
mimic increased myelin phagocytosis compared to negative control. Finally, in 
vitro experiments suggest that supernatants collected from LPS-stimulated 
mouse BMDMs transfected with a miR-146a mimic do not affect neurogenesis or 
oligodendrogenesis. 
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Densitometry Procedure Using ImageJ 
 
This procedure is based off of the ImageJ (Schneider et al., 2012) online user 
guide (IJ 1.46r), Section 30.13 (Ferreira and Rasband, 2012), and tutorials by 
Luke Miller (Miller 2010) and Tim Starr (Starr, 2013) with modification. 
 
Image Set-Up 
 
1. Scan coloured copies of your x-rayed western blot into a TIFF file of at 
least 600dpi resolution. Ideally, the blot should be clean with little variation 
in background. 
2. Open scan in ImageJ, and change to Grayscale: Image -> Type -> 8-bit. 
Save scan as a TIFF file. 
3. If the bands of interest are not lined up horizontally, rotate the image. To 
do this, go to Image -> Transform$ -> Rotate$ . Check only Preview, set 
Interpolation to None, set Gridlines to desired number, and adjust the 
angle accordingly until the bands are horizontal. Positive angles turn 
image clockwise, negative angles turn image counterclockwise. Once the 
image is adjusted accordingly, save the image again as a TIFF file. 
 
Measuring Density 
 
4. First, make a rectangular selection of the first vertical lane over the band of 
interest. Make sure the rectangle is longer vertically than horizontally. 
Once selected, go to Analyze -> Gels -> Select First Lane (or do 
Command + 1 on a Mac). A “1” should show up inside your selection.  
5. Click inside your selection with the “1”, and drag the copy of your selection 
over to the next lane over the band. Do not adjust the size of the selection 
in any way, and don’t worry if your new selection doesn’t line up with the 
first selection (the program will fix this later). Once you have your selection 
over the band in the row, go to Analyze -> Gels -> Select Next Lane (or 
Command + 2 on a Mac). Now, a “2” should appear in your new selection, 
and the selection should have “snapped” to the same height as the 
selection for the first lane. Repeat this process for the rest of the vertical 
lanes. 
6. After you select the last lane, make sure the last selection is still “selected” 
or “highlighted” with the small white squares around the perimeter of the 
selection (or else the next step will not work). Then, go to Analyze -> Gels 
-> Plot Lanes (or Command + 3 on a Mac). ImageJ then plots graphs of 
your bands with the first lane as the top plot, the second lane as the 
second plot, etc. The bands are displayed as “peaks”. 
7. Using the straight line tool, make a straight line from where the peak 
begins on the left to where the peak ends on the right, the “base” of the 
peak. This will be subjective, but try to be consistent when choosing when 
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the peak starts to go up, and where it starts to level out. Note that peaks 
can vary in width, depending on if the band is wide or narrow. You are 
trying to remove the “background” from the band.  
8. Once you have made straight lines across the bases, choose the “Wand 
(tracing) tool”, and select the area of the peak that you have enclosed with 
your line. An outline of the area will appear, and ImageJ will provide you 
the area of that peak that it measured (the density of the band). Continue 
clicking on the areas for the rest of the peaks to get the areas of those 
enclosed peaks. Copy and paste the results into Excel. Don’t forget to 
save the plots as a TIFF file, and take a snapshot of the grayscale image 
with your lane selections for future reference. A image of a sample peaks 
and blots for actin is shown below using this technique: 
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Analysis 
 
9. Repeat the above procedure for other blots, including those with loading 
controls for your bands (such as actin).  
10. Once you have the areas for you band of interest with it’s loading control in 
Excel, perform the following calculation to normalize the band per lane: 
 !"#$%&'"! "#$%&'!!"#$!%&'(!!"!!"#$%$&#!!"!!"#$ 
 ! !!"#$%&'!!"!!"#$%&'!!"!!"#$%$&#!!"!!"#$!"#$%&'!!"!!"#$%&'!!"#$%"&!!!!!"#$ !!!!"" 
 
11. Graph your relative densities.  
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